No retraction, correction or concern found when last checked on Oct 25, 2026.

Unraveling Plant Natural Chemical Diversity for Drug Discovery Purposes

Emmanuelle Lautié, Olivier Russo, Pierre Ducrot and 1 more

Frontiers in Pharmacology · 2020 · Review · CC BY

doi:10.3389/fphar.2020.00397

Abstract

The screening and testing of extracts against a variety of pharmacological targets in order to attempt benefiting from the immense natural chemical diversity is a concern in many laboratories worldwide. And several successes have been recorded in finding new actives in natural products, some of which becoming new drugs or new sources of inspiration for drugs. But in view of the vast amount of research on the subject, it is nevertheless surprising that not more drug candidates were found. In our view, it is thus fundamental to reflect upon the approaches of such drug discovery programs and the technical processes that are used, along with their inherent difficulties and biases. Based on an extensive survey of recent publications, we discuss the origin and the variety of natural chemical diversity as well as the strategies having the potential to embrace this diversity. It seemed to us that some of the difficulties of the area could be related with the technical approaches that are used, so the present review begins with synthesizing some of the more used discovery strategies, exemplifying some key points, in order to address some of their limitations. Thereby, it appears that one of the challenges of natural products-based drug discovery programs should be an easier access to renewable sources of plant-derived products. Maximizing the use of the data together with the exploration of chemical diversity while working on reasonable supply of natural product-based entities could be a way to answer this challenge. We thus suggested alternative ways to access and explore part of this chemical diversity with in vitro cultures. We also reinforced how important it was organizing and making available this worldwide knowledge in an “inventory” of natural products and their sources. And finally, we focused on strategies based on synthetic biology and syntheses that allow to reach industrial scale supply. Approaches based on the opportunities lying in untapped natural plant chemical diversity are also considered.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 25, 2026. Paragraph numbers are ours, so an answer can point at one.

Drugs and Natural Products

1Several reviews, like the updated survey from, pointed to the fact that many drugs on the market are from natural origin; these authors stated that, out of the 1,328 new chemical entities approved as drugs between 1981 and 2016, only 359 were purely of synthetic origin. From the remaining ones, 326 were “biological” entities (peptides of more than 50 residues, including therapeutic antibodies), and 94 were vaccines. A little less than half of those new drugs (549, exactly) were from natural origin or derived inspired from natural compounds. Furthermore, in the anticancer area, out of the 136 approved nonbiological compounds from the same period (1981–2014), only 23 were purely synthetic (i.e. not derived from natural compounds nor natural compounds themselves). Natural origin can have different definitions, and these authors accounted for three categories: unaltered natural (pure) products; defined mixture of natural products (NP) and natural product derivatives isolated from plants or other living organisms as fungi, sponges, lichens, or microorganisms; and products modified by medicinal chemistry. There are many examples: anticancer drugs such as docetaxel (Taxotere™), paclitaxel (Taxol™), vinblastine, podophyllotoxin (Condylin™), or etoposide; steroidal hormones such as progesterone, norgestrel, or cortisone; cardiac glycosides such as digitoxigenin; antibiotics like penicillin, streptomycin, and cephalosporins [see IA Ross for more examples (1999)]. Furthermore, pointed to the fact that fragments derived from natural structures are a source of diverse molecules from which new drugs can be designed, thanks to the fragment-based drug discovery approach.

Screening for New Drugs and Discovery Approaches

2Besides the understanding of pathological processes, the source of molecules has been a main concern for the pharmaceutical industry. Vast libraries of compounds have been established in order to feed the research. For example, in midsize pharmaceutical companies, it is common to find libraries from 30,000 up to 500,000 compounds, while for big pharmas, the numbers are more in the 500,000 to several million ranges. To our knowledge this is also the case for the National Chinese Compound Library in Shanghai, China (http://en.cncl.org.cn/). Finally, national or transnational efforts have been reported to create such depositories of compounds for the use of screening programs from the Academy: see in Europe and for the NIH/NCI effort. In addition, vendors are also selling libraries of compounds composed of a “large” diversity that they build according to different principles. Several publications deal with how the compounds are chosen, if they are following Lipinski rules or not, if they are virtual or real, if they are systematically tested on all the targets, how they can be organized in subclasses of compounds designed to potentially interact with channels, receptors, or enzymes, etc. Furthermore, the composition of the library in relation with the main categories of molecules—small synthetic compounds, drug-like organic compounds, peptides, proteins, sugars, nucleosides, or natural compounds—can greatly vary in function of the “Pharma company culture”, that is to say, the compounds that have already been synthesized in a given company as well as the “sensitivity” of the medicinal chemists and screening people.

3When the decision to incorporate natural products is made, pure well-defined compounds or extracts are selected according to different criteria: pharmacognosy, ethnopharmacology, or even traditional knowledge. Because of the traditions existing in the uses of botanicals and medicinal plants, this empirical knowledge has accumulated for ages and passed through generations. Modern pharmacology has explored and validated probably only a minor part of this knowledge through attempts of rationalizing the use of plants as sources of drugs. This first possible approach would be a way to guide some drug discovery projects. Another totally different approach based on the use of high-throughput screening (HTS) emerged one or two decades ago. It aimed at exploring systematically the immense chemical diversity in secondary metabolites and was based on the technological developments of discovery tools such as miniaturization and automation. In this sense, the increase of the amount of compounds was tested simultaneously, and the scientific rationalization of the selection of those compounds, thanks to the growing capacities of chemo-informatic approaches, emerged as trends in HTS.

Strategies for Identification of Bioactive Compounds From Crude Extracts

4When reviewing the literature on how discovery of plant-derived actives is performed, the following pattern emerges. Plants are collected in precise geo-localized sites. The collection may include the whole plant or any part such as leaves, stems, bark, seeds, or roots. Then, the botanical material is dried and powdered using mechanical means, such as grounders. Those powders are then extracted with solvents at different temperatures or of increasing polarities with sequential extraction procedures in the cases when, for example, the chemistry of the active compounds is unknown. These first steps are important to consider as the extraction method might influence the chemical composition of the extract and consequently, its biological activity.

5Then, the extracts are dried under low pressure, and the final solid residue is suspended in a solution comprising the minimal amount of a biological-compatible solvent, often DMSO. The next steps would include the testing of the extracts in 96 (or 384) well plates against the biological targets of the program. These biological tests are often a cloned enzyme catalytic assay, a receptor binding assay, a protein–protein interaction assay or even a whole pathway, to name but a few. Biological testing targeting whole-cells was also reported against cancer cells, virus-infected cells, or microorganisms. Extracts showing activity on those tests are selected and submitted to fractionation by chromatography. Each fraction (typically around ten) will be tested in turn in the same assay, and the active fractions are subjected to one or several extra fractionations, often using alternative chromatographic conditions.

6Some of these experiments are based on an HTS environment. HTS methodologies provided us with impressive progresses in terms of increased speed of assay and lowering of price. Indeed, robots can handle several thousands of tests during a workday. However, the initial enthusiasm for HTS when applied to crude extract libraries in targeted assays systems has been facing several issues as stated recently by. In fact, HTS techniques do not really modify the discovery process itself. For example, starting with 2,000 extracts—which is a modest number considering (a) the number of plants species available and (b) the number of compounds in an HTS campaign—might result into 10% actives, in the best case. Thus, the next step would be 200 hydrophobic columns, with the collection of about 10 fractions per chromatography, and then 2,000 tests. As exemplified, the real bottleneck in this whole process is the parallel fractionations of the actives; as of today, only partial progresses in their automatization have been reported over the last years.

7Other strategies have been developed that delivered results. In their detailed review, classify into five groups the strategies to identify bioactive compounds from plant extracts: the bioactivity-guided fractionation strategy previously mentioned, the similar synergy-directed fractionation strategy, the metabolic profiling strategy, the metabolism-directed (biotransformation focused) strategy, and finally the direct phytochemical isolation strategy. The group of metabolic profiling approaches has a more detached relationship with bioactivity as they are not focused on compounds. They were developed during the last 10–15 years in plant natural products. Using highly sensitive and reproducible analytical methods, they allow the correlation between chemical profile (qualitative or quantitative) and bioactivity data with recent progress in the field of data analysis and integration at the extract level. Finally, the group of direct phytochemical isolation approaches focuses on the comprehensive chemical characterization of the plant extract and the isolation of novel scaffolds without immediately evaluating their bioactivity.

Successes and Limitations

8Some of the successes in terms of new drug development have already been mentioned in Drugs and Natural Products. But in terms of screening and strategy for finding an active compound in an extract as an enzyme inhibitor or a protein/protein interaction inhibitor, many successes have also been reported. Some examples of screening results of extracts with those approaches can be mentioned here, but being exhaustive is impossible, as literally hundreds of such tests were performed [e.g. from our laboratories and from hundreds of others]. Some examples reported recently are given in Table 1 of the inhibitory activities of plant extracts on specific enzymes. Of note, the panel of enzyme activities is large and diverse; the examples in Table 1 reflect the current trend in terms of enzyme of origin for this type of work: they are mainly coming from cancer and diabetes/obesity fields. It is important to say that an unknown number of failing attempts remain unpublished.

9For the last thirty years screening for new molecules—whether candidate drugs per se or hit compound that should be modified—is one of the two main sources of drugs for the pharmaceutical industry. These screening strategies delivered mixed results, and several factors complicated dramatically the analyses of these results. The main ones are in our opinion: the way diseases can be simplified—or not—to a molecular target that is amenable to HTS; the choices of the molecules which can be screened into these assays; the quality of the assays and/or their sensitivity; the statistical considerations to determine the threshold at which a compound is recognized as an active; and finally, the source of the screened molecules. We and others exposed our screening strategies at several occasions, and considering the diversity of the potential problems, it can be hard to identify a universal approach. This is a fact that HTS promising techniques have not delivered as many drugs as expected with regard to the price and the ambition of the solutions/organizations involved.

Several Limitations in the “Classical” Strategies to Identify Bioactive Natural Products

10The first type of limitation would be related to the collections of living organisms and access to plant species, for example. The probability still exists that a plant collected on a given location would not be there the next time around, especially the whole plant. If bioactivities associated with this species are discovered during the process, it could be hard to find again the same plant population. In those cases, two choices are possible: to look for this species in another location or to look in the same location for a closely related species with the help of botanists. Neither solution is entirely satisfactory: the change of harvest location can imply change(s) in secondary metabolite production as their biosynthesis generally depends on the control by both biotic and abiotic factors. Furthermore, the other species of the same genus might very well express different genes coding for proteins acting slightly differently in biosynthetical pathways leading to different compounds or to the same compounds synthetized in different proportions (see below for discussion on diversity). Moreover, if the collected species are not properly reported following the correct taxonomy, the harvest might be even more difficult to reproduce: thereby, a table of correspondence between the names mentioned in this review (and used in the articles of origin) and the accepted plant species names is provided in the supplementary data ( Table S1 ).

11Another type of limitation is related with the fact that groups performing bioguided discovery of new actives are often confronted with similar problems: (a) the active extracts, once fractionated, do not maintain the level of activity; (b) the whole long and difficult isolation process leads to a molecule that is mundane or known for decades; (c) the final product quantity in the remaining active fraction is too small to hope for a structure elucidation; (d) going back to the location of origin, the same plant population is not found anymore or if the plant is found, the same extraction treatment led to an apparent lack of active fraction(s) on the same target. Most of those events are not discussed in publications, obviously. Therefore, this bioguided approach, existing with small variations––mostly technical––is paved with difficulties that are more than often discouraging at least for an industry or for big programs.

12As discussed in many instances and particularly well summarized by, one of the key starting points is the choice of the pharmacological assay used for the screening. The fact that the targeted disease is obviously more complex than the molecular target it has been simplified to, is universally recognized, but alternative approaches remain elusive or still difficult to set up. For example, the disease could also be simplified by a phenotypic change of a cell originating from a diseased organ using the stem cell differentiation approaches. After treating such a model with NP extracts—having potentially hundreds of compounds—reverse pharmacology should allow recognizing the actual target of the NP compound as the lysed cell extract is chromatographed to retain the target proteins. Nevertheless, cellular phenotypic changes are extremely complex to understand, and this approach has been more than once extremely frustrating despite some successes, outside of the NP recognition area. Actually, another limitation of this approach is linked with working with complex mixtures in NP discovery as sometimes several compounds could contribute synergistically to the global action on a disease: like for example the compounds (at least three of them) derived from leaves of Salvia miltiorrhiza (red sage) that are reported to act at many different levels of liver fibrosis. This kind of observation would strongly argue against the strategy described in here aiming at the discovery of the main pure drug-like compound in a plant extract. In summary, such approaches (phenotype screening and reverse pharmacology) would require disease models that are far from being the current available systems.

Limitations Related to the Need of Market-Compatible Amounts

13In the domain of drug production, a fact is that around 60,000 tons per year of salicylic acid are produced synthetically worldwide (https://ihsmarkit.com/products/chemical-technology-pep-reviews-salicylic-acid-2003.html), and this figure translates to 80 billions of pills. That is to say, that in order to benefit patients, critical amounts of a potential drug need to be considered, and the access to the identified NP as well as its availability are critical. For example, at the start of the Taxol™ story, the compound was isolated from Taxus brevifolia bark. Ten kilograms of bark was necessary to obtain 2 g of the pure compound needed for the treatment of one patient. For the clinical study, 12,000 trees were cut down to obtain the 2 kg necessary for the studies leading to the approval of the compound. In fact, the antineoplastic Taxotere™ is now produced by hemi-synthesis from the precursor 10-deacetyl-baccatine III, which is isolated from leaves of Taxus baccata. In other words, an alternative had to be found to the initial procedure taking a too heavy toll on trees of the initial species. Another interesting figure dealing this time with herbals is the annual demand of ginseng roots around 50,000 tons. This kind of figures embodies a major limitation to new drugs originating from NP that is sometimes disregarded by research laboratories: there is a real challenge for the use of NP in reaching a tonnage compatible with the drug market.

14Another reason for which NP based projects might be challenged for consideration by the industry is the small amount in which natural compounds generally accumulate in plant tissues. Indeed, structural characterization as well as biological testing can be made more difficult. Nevertheless, many progresses have been done in this area: in relation with structural characterization, for example, considering the growing sensitivity of the analytical methods and instruments, it will not be long until the barrier of the microgram for the determination of the structure of a compound would be reached. The analytical techniques for structural elucidation of an unknown compound are based on a mixture of spectroscopy (infrared, UV, Raman), mass spectrometry, and nuclear magnetic resonance (proton and C13 NMR). Nice examples of such task are described in various publications while difficulties are also discussed by. Advances in NMR techniques were reviewed, and several examples of compounds for which structures were solved with mass of pure compounds lower than 100 µg were reported. In fact, the situation could be different from one plant to another or from one organ/tissue to another, even in a single plant species. Therefore, even if we can identify the many compounds in each sample while being able to establish their structure, it would be more straightforward to consider the feasibility of the systematic compendium of all the plant chemical components.

15A careful understanding of the metabolic pathways of the tissues of the plant species from which the product has been isolated is also necessary. It is especially the case when hemi-synthesis is to be used to perform the NP’s industrial production. Instead of using a vital organ of the plant in which the compound is in fair concentration, one tries to find a precursor of the product in a renewable part of the plant, like the leaves. For the hemi-synthesis of Taxol™, 30 km2 of T. brevifolia fields in the Yunan province (China) consists in the main source of precursor for (http://www.yewcare.com/index.php cited in ). Certainly, the use of a renewable source of the natural product is desirable, and often enough that such sustainable and profitable solutions are found, as proven by the 40% of the available drugs in the Pharmacopeia that are from natural origin. Many examples of drugs from natural origin exist, one being found in the still common use of plant sapogenins, alkaloids, or sterols for the production of steroids for human drugs (sex hormones, corticosteroids, contraceptive drugs, etc.). Other examples involving hemi-syntheses modifying the NP can be given: quinine (at least 100 tons per year), camptothecin, cocaine, camphor, vitamin B12, etc. Interestingly, at the other end of the spectrum, extremely simple molecules also of NP origin like salicylic acid for pain (J. B. ) or metformin for diabetes see their production reach industrial scales by total syntheses using standard organic chemistry.

The Need for Easy Access to Chemically Diverse Compounds

16Testing as many compounds as possible with chemically diverse structures is important in order to have better chances to discover new drugs. Indeed, the affinity of a drug to a target is the result of shape and electrostatic potential complementarity between the drug and the binding site as well as binding kinetic related properties such as desolvation and conformation changes upon binding. Ligand flexibility therefore plays an important role in identifying partially fitting chemicals as starting points further optimized by medicinal chemistry.

17Screened compounds need to be diverse in shape and electrostatics to match any of the 3,300+ binding site, as listed in the pocketome, as well as diverse in structure to allow thorough optimization. It is noteworthy that the probability of identifying a hit considerably decreases with the increasing complexity of the ligand. The complexity of a molecule increases with the size and the atom connectivity. As a result, the more complex they are, the greater the number of molecules one should screen. Statistical analyses have been performed on natural products to study their chemical diversity, molecular properties, scaffold diversity, and coverage of the chemical space. Comparisons between NP and other compound collections have also been performed, showing that NP differ from drugs and synthetic compounds in several aspects. NP are considered complex due to their number of asymmetric centers, their number of Sp3 carbon ratio in rings, and their number of ring junctions. Indeed, NP display in general more chiral centers than drugs, although their number of chiral centers to number to carbon atoms ratio may be lower. Although there is no clear evidence that this complexity is necessary for their biological activity, it greatly impacts their specificity. NP also display a great diversity in their scaffolds. For instance, the GreenPharma database contains 55,185 Murcko frameworks for 302,000 natural products (18.3%), whereas NCI and ChEMBL databases contain a little of less NP-derived scaffolds: 13.1 and 13.6% respectively.

18An interesting representation of the divergent diversity between bioactive NP and synthetic compounds can be seen in Figure 1. This graph reported by shows, on a small sample of compounds (126,140 natural compounds versus 178,210 medicinal chemistry-issued compounds), the difference in repartition between these two populations after a principal component analysis. NP are also considered biologically diverse compounds that can hit a vast diversity of biological targets. Most of them have a single known target, with a mean of 2.66 targets and only few highly promiscuous compounds. However, biological activity is reported for only 2% of the NP. An extended study using docking experiments of NP in 332 targets showed a mean of 2.14 targets per natural products, while in comparison, drugs interact in average with 3–6 targets, and 50% of all drugs might exhibit activity against more than five targets.

19For all these reasons, there is a strong need for an easy and organized access to chemically diverse structures in the form of libraries of compounds. It is necessary to keep a good balance between diversity, defined as the mean of compound’s pairwise dissimilarity and structural redundancy to ensure greater diversity of hits at an overall hit rate in the range of 0.5 to 2% and 20–40% within an active chemical series. In addition, these compound libraries are required to be constantly enriched with compounds filling the gaps in the molecular space. Interestingly, stated: “diversity within biologically relevant chemical space is more important than library size”, this biologically relevant chemical space being defined by protein-binding sites for potential ligands. Another point emphasized by these authors is that while the commercially available chemical space is wider than the explored natural product universe—the first one is evaluated to 5.109 compounds, while the second only represents 3.105 compounds—NP are intrinsically more diverse. A major component of this comparison is that NP are more complex, from a chemical point of view, leading to greater shape diversity. However, NP might not be the best compounds to screen in HTS campaigns due to their complexity (“best” in a drug-discovery perspective). Indeed, their probability of being active on a random target is lower, and their chemical tractability is far from optimal. Although NP decently occupy the biologically relevant chemical space, and 80% meet the criteria to be considered as drug like compounds, their complexity might be the bottleneck during the optimization phase of the lead compounds.

20Thus, acquiring as many diverse compounds as possible is necessary in drug discovery programs, and the exploration of natural existing chemical diversity would be a must. Nevertheless, not only the design of those libraries, but also the design of the assays and the understanding of the pathways that are responsible for the targeted pathologies need to be relevant and well understood. In summary, the main idea is that if compounds as chemically diverse as possible are necessary to feed drug discovery programs, then a great deal of efforts should still be invested in the exploration of natural chemical diversity because, in this particular context, natural chemistry is more advanced than organic chemistry. After this introduction on the background of NP in the area of drug discovery, we aim at discussing and showing the extent of natural chemical diversity (Natural Chemical Diversity) as well as the strategies of having the potential to embrace this diversity (Different Strategies to Benefit From This Diversity) based on an extensive survey of recent publications. A preliminary survey on the main origins of recently reported natural compound structures’ literature was performed by taking a complete volume from a journal that is considered as a gold standard in NP (J. Natural Products, 2018, vol 81). Then three different tables mentioning the species of origin and the type of compounds newly reported in 2017 and 2018 in several journals selected for their specialization in the area (like for example Journal of natural products, Planta medica, Tetrahedron Letters or Natural products communications) were built upon this sampling. Finally, Different Strategies to Benefit From This Diversity offers some strategic and technical proposals based on our interpretations of the trends of the field supported by recent ad hoc literature.

Natural Chemical Diversity

21The chemical diversity of NP is known to be extremely wide, and it can be divided in several types representing a challenge for the chemist and the biologist.

Diversity of Origins in Natural Compounds

22Diversity can be measured and quantified by many methods some of which have been used for decades to qualify the product library diversity. Our first survey showed the main origins of the molecules reported as natural compounds in 2018: they were classified between those coming from animals (2.6%), from fungi and lichens (9.3%), from microorganisms (12.9%), from marine organisms in the broadest sense of the term (13.2%), and from plants (44.1%), while the papers dealing with partial or total syntheses of natural compounds (19) and about 20 others describing various methodologies of analyses were put aside. As shown, in 2018 plants were still the main source of “new” natural compounds.

23Then, by sampling the recent ad hoc literature, three different tables were constructed gathering the origin of new compounds reported in 2017 and 2018 in several journals selected for their specialization in the area. Although plants were our main focus, we thought it might be useful to also consider other sources of diversity from other living kingdoms as they also consist of very interesting sources to explore and because some of them are somehow related to plants: it is especially the case for compounds which functions in plants are related with defense and other ecological interactions as compounds “optimized by evolution” according to Gunatilaka in its review on natural products from plant-associated microorganisms. Among the 240 papers that were reviewed, a handful described compounds isolated from venoms and toxins originating from marine organisms and animals (insects, snakes, and alike). Then, a few other papers described compounds coming from microorganisms as can be seen in Table 2. Microorganisms, such as bacteria and yeasts, were traditionally important sources of antibiotics and are still a source of new peptides, but here compounds other than peptides can also be found that are close to secondary metabolites naturally synthesized in those cells. New peptides are more often described in journals specialized in peptide chemistry and pharmacology, even if their source is a living organism. Table 3 gives examples of compounds isolated from lichen, fungi, and sponges. The chemical diversity of these compounds is interesting but, as of today, growing lichen or sponges is not so much reported and might turn out to be difficult on a larger scale. On the other hand, secondary metabolites synthetized by microorganisms growing in extreme conditions might also be difficult to obtain in large quantities. It would be therefore interesting to dig deeper in this area, as it has been done elsewhere for other purposes: biotechnological, industrial, pharmaceutical, or ecological. Finally, Table 4 gives many examples of compounds isolated from different plant species and different tissues from these species.

24As plants are one of the major sources of “new” compounds, the following sections will deal with their diversity.

Diversity of Plant Species

25As mentioned, the compounds reported from plants ( Table 4 of our survey) originated from 165 different plant species, from trees to ornamental plants and harvested in very diverse areas from Australia to Antarctica.

26In fact, a total of 146 different genera were represented from 82 different botanical families, only six of which are not Angiospems (two ferns, two liverworts, a moss, and a spikemoss). Most of them, around 93%, are thus from the flowering plant group ( Figure 2 ). Furthermore, it is interesting to observe that the remaining 76 families from which these new compounds were reported represent a small part of the total 416 botanical families defined in the last 2016 update of the Angiosperms Phylogeny Group. As illustrated, most of the new compounds of our survey were isolated from the superasterids and superrosids, major clades from the eudicots. Indeed, this small survey illustrates how a large proportion of plant species still remains underexplored, not only in the Angiosperms but between all taxa of Plant kingdom.

27Furthermore, it is important to consider that new species of plant are discovered quite often: for example, 2,034 new plant species were recorded in 2014, including at least one tree species. So far, 310,000 plant species have already been described, among which authors estimate that only 6% have been investigated pharmacologically and 15% phytochemically. It clearly indicates that even more compounds remain to be found in plants.

28It is also interesting to observe that reviews such as teach us that plants from different taxa can also synthesize identical although rather complex compounds.

29Gene duplication and neo-functionalization leading to the extension of the existing metabolic pathways are both part of the mechanisms that have been identified in plants as responsible for diversification of secondary metabolites together with the influence of ecological factors: for example, it has been suggested that, from a small group of precursors, plants would synthetize a full range of highly diverse compounds rapidly changing that are “screened” for their biological activity afterwards as mechanisms of adaptation that would help plants cope better with biotic and abiotic pressures. This ecological understanding of plant secondary metabolite diversification also contributes to the anticipation that the more plants species are described, the more diversity is to be found in the end-products of these pathways along with possibly valuable “new” compounds. A recent interesting study discussed the chemical Angiosperms’ diversity among natural products and some of these evolutionary mechanisms leading to diversification of chemical structures in function of the group of secondary metabolites (flavonoids, tropane alkaloids, sesquiterpene lactones, and betalains). They use the ChemGPS-NP developed previously by their group as tool to localize compounds in the chemical property space, “measuring” this way the chemical diversity.

30In other words, the preservation of ecological niches and plant biodiversity will also serve our interest in terms of chemical diversity for possible applications. And, interestingly, at higher trophic levels, it will also contribute to biodiversity, creating in turn other biotic pressures on plants that may adapt by synthetizing other compounds!

Chemical Diversity in Plants Related to Space and Time

31As plants are multicellular organisms with organs specialized for different functions, it seems logical to think that some biosynthetic pathways could be turned on or off depending on the part of the plant studied and that a certain level of diversity can exist within the plant tissues. The main parts of the plants that are classically separated are roots, twigs (stems), leaves, flowers, fruits, and seeds. Of course, constraints of collection make some of these parts more suitable than others. Our survey in Table 4 details for each one of the 165 reported plant species the plant part from which it was isolated. Figure 3A summarizes the proportion of new compounds reported in different plant parts in our survey. For comparison, Figure 3B shows similarly the organs/parts of origin of the active compounds reported from the 49 plants described in Ross work. It seems that in both cases, most of the studies are done on leaves. On the other hand, it is not clear, on a systematic basis, if what was found in the other organs can be found as well—even in small quantities—in the leaves. Nevertheless, leaves are the most accessible part of any plant, and they are renewable which allows preserving the whole plant. Obviously, it is also valid for fruits or flowers, but their availability may be subjected to seasonality.

32Indeed, often enough, a compound is described from a part of a given plant. It seems interesting to emphasize that it does not necessarily mean that it is the main component or a major component of this plant part. It can be accumulated in superior amounts in other tissues of the same plant. Indeed, in plant descriptions such as those in Ross work, the author described the way plants are used in traditional medicine. The different parts of a given genus can be used alone or in mixtures in preparations ranging from infusion, maceration, decoction, juice, dried powder, or even fresh organs (fruits, leaves) ingested as such. Astonishingly, those recipes were collected from scattered geographic places. This last observation suggests that traditional medicines around the world independently found similar remedies to similar diseases and sometimes with the use of related plant species.

33Another interesting source of intraspecific chemical diversity is the environment of the plant cells biosynthesizing the chemical compounds of interest: it is well known that compounds produced by the same plant species can vary in nature or quantity depending on the environment (localization or time of the year) or the part of the plant where it has been extracted from. pointed out in particular the plant ontogeny, but also genetic and environmental variations as major sources of diversity for plant secondary metabolites. The existence of chemotypes is another example of this intraspecific chemo-diversity well described for example in plants producing essential oils. Factors like moisture, salinity, temperature, or nutrition levels are known to influence the essential oil production, and the genotype could also significantly influence the chemotype as it was shown recently for Valeriana jatamansi Jones. The biosynthesis of natural products can also differ in function of the different individuals from the same population. It is the case, for example, when these compounds are related to antimicrobial activity as summarized by in their perspective article on chemical diversity linked with plant defense: these compounds can be synthetized constitutively as part of normal plant development—and stored in specialized tissues—or synthetized in response to pathogenic challenges through the activation of the transcription of specific genes of the corresponding biosynthetic pathways.

Diversity of Chemical Skeletons and Structures

34Based on the number of genes, it has been estimated that the plant kingdom contains more than 200,000 different metabolites with values for single species ranging between 5,000 and 15,000, values that are significantly greater than those of microorganisms (∼1,500) and animals (∼2,500). But it is not only the global absolute value of chemically diverse compounds that is interesting. Such diversity and such dynamicity are indeed a wonderful wealth of chemical structures, source of inspiration for medicinal chemist, once the structure is carefully identified, and the related pharmacological activity is screened. But it can also become a source of complexity for the phytochemist working on the structure or on the structure/activity relation.

35Classically, within this chemical diversity in plant secondary metabolites, the nomenclature used by pharmacologists to attempt classifying several families of natural compounds such as polyketides, phenylpropanoids, terpenoids, steroids, or alkaloids is based more on their biogenesis and the pathway they originate from (acetate, shikimate, mevalonate or methylerythritol phosphate pathways) or their combination, than their structure itself. And even within a defined group, the diversity can be impressive: for example, the terpenoid family is suspected to contain at least 50,000 different molecules while at least 12,000 flavonoids have been described. Certainly, how “different” these molecules are could be further commented, but as discussed below, apparently minor differences (for example a methyl or a hydroxyl moiety) might dramatically change the molecule’s pharmacological properties.

36In the data gathered in Table 4, as previously commented, it can be observed that even in the same plant species and same organ, different compounds have been characterized like jozilebomines and dioncophyllines in Ancistrocladus ileboensis leaves (J. d; J. c) or xanthohumol and α-acid derivatives such as humulones in Humulus lupulus flowers (J. b; R. ). Nevertheless, these compounds might only be slightly different from each other in terms of skeletons as illustrated in the following example: the compounds which structures are shown in Figure 4 were recently isolated from six different species of Euphorbia. They are all diterpenoids that slightly differ in their structures: ent-abietane derivatives (structures Z1 and Z2) (C.-J. ), gaditanone (structure AA), ingenane derivatives (structure AB), premyrsinane and tigliane derivatives (structure AC), dideoxyphorbol ester (structure AD), sooneuphoramine (structure AE), jatrophane analog (structure AF), and other abietane derivative (structure AG). These compounds all originated from the same biosynthetic pathways where the cyclization reactions of the precursor geranylgeranyl diphosphate and several rearrangements allow many structural variants of diterpenoids to be produced. It is interesting to notice that despite a homology in term of basic scaffold (a phorbol ring system with some rearrangements), all the compounds are extremely different from each other from a chemical point of view.

37This last statement requires underlining that the difference between two chemicals can be dramatic concerning their biological activities while minimal concerning their chemistry. For example, the chemical difference between testosterone and estrone is a saturation of the A cycle of the cholesterol backbone. These minor chemical differences leading to massive differences in pharmacological potential have been the source of a never ending debate among screeners in the pharmaceutical industry on what should populate chemical libraries: should minor variations of basic skeletons be included or not (in the primary screening) knowing that a missing methyl could lead to a nonactivity and vice-versa? In our view, it seems important to gather as many compounds as possible inside a chemical series, even if the diversity seems to be futile, because, by setting the minimum results at a poor but significant level, such as 1 to 10 µM (depending on the molecular target) hits could be found, and even minor differences in structures can lead to new leads. In this sense, working with phytochemical diversity as shown in Figure 5 becomes meaningful.

38Furthermore, most of these compounds would be difficult to obtain by conventional organic chemistry methods, not only because of the presence of several intramolecular bridges, but also because of the stereochemistry of the final product [see for example discussion on isoprenoids]. Secondary metabolites are the results of multienzymatic pathways, and all these enzymes have a strict stereo-specificity. These multiple possibilities in terms of spatial arrangement in compounds contribute to the wide range of pharmacophores lying in natural products.

39It seems interesting not only to mention the plant chemical diversity but also to show it with some interesting and diverse structures: Figure 5 already presented about 20 different chemical skeletons of NP that are reported in Table 4 (compound appearing in bold cases). More diversity is presented in Figure 6. To be noticed that compounds issued from microorganisms are often—but not always—peptide-derived structures, often macrocyclic compounds, such as the families of antibiotics found in Penicillium and the like, and thus are not the main purpose here.

40However, it is a fact that the structures presented in Figure 6, even if they are almost randomly chosen, are different from what provides the current state of the art in medicinal chemistry. This is not really surprising when considering that 83% of core ring scaffolds shown in natural products cannot be found in libraries of synthetic compounds. It should be reminded that part of the interest in “discovering” such structures, if they have any biological activities, resides in our capacity to use medicinal chemistry to translate such complex structures in simpler molecules amenable to the industrial production. At the same time, those structures might bear activity towards proteins, the inhibition of which has not been reached yet, with our current access to chemical synthons. This has been reported and discussed according to two points of view: (a) the natural compound-derived fragments and (b) the list of compounds issued from natural skeletons: what called NP derivatives in which 268 out of 1,328 new drugs can be found. Among the classical examples, there are vincristine and vinblastine as part of vinca-alkaloids, statins, glifozins, and ingenol mebutate. It should be reminded here that the current process is moving more from “simple” hits—from whatever origin—to more complex molecules by means of medicinal chemistry decoration of these synthons. The process of lead hopping, as defined by and, should theoretically permit to mimic one complex structure by another, simpler one. All this body of techniques and theories should be put together at work in order to gain new powerful compounds from new, NP-based approaches.

41In fact, a survey of the data indicates two important features of NP, on the basis of this selection: 1/compounds are very diverse even if they include some common features (like for instance the particular cycloheptanic structure found in some of the main compounds from Euphorbia—see Figure 4 ) and 2/the high number of asymmetric carbons render their synthesis by standard organic chemistry difficult if not impossible. For instance, some examples of those numbers are given in Table 5. Considering that the number of theoretically possible isomers is 2n, n being the number of asymmetric carbons, in some cases, the total number of possible isomers is in the several thousand ranges (see numbers in Table 5 ). Nevertheless, a series of impressive chemical papers reported complete syntheses of such compounds by “standard” synthetic organic chemistry, even if the up-scaling of such tour de forces remains to be addressed.

Different Strategies to Benefit From This Diversity

42As previously mentioned, a deep interest lies in searching and exploring the immense plant chemical diversity for drug discovery purposes, but the strategies to do so need to be reevaluated. Indeed, most of the natural secondary metabolites mentioned herein are not—so far and by far—easily synthesized. It is still through harvesting that we can use plants for discovery and development purposes or for industrial scale production. Compounds with a superior pharmacological activity isolated from a plant part must be isolated from plant extracts where they lay in minor amounts. Certainly, as previously discussed, this is a main bottleneck for many applications, as it is time-consuming, the “superior activity” can vanish in the process for several reasons, or a compound of already known activity can be rediscovered at the end of the process.

43In our view these limitations can be overcome by developing alternative strategies. Among these strategies, it seems that the following ones could help solve some of the difficulties linked to NP discovery programs. The first one focuses on gaining systematic access to compounds from plant parts: it deals with the use of scalable cultures of plant cells remaining capable of producing these specific chemicals. It would allow to bypass repetitive massive in natura harvests and to have the opportunity to go back to the biological material for further chemical explorations of the remaining compounds, if some of its own limitations would be overcome. The second strategy aims at the appreciation of the known plant chemical diversity, through an “inventory” of NP sources. The third strategy focuses on the industrial scale production through synthetic biology, a branch of biotechnology by which one can construct inside a microorganism the enzymatic pathways leading to a given compound. This last body of techniques leads to the possibility to grow thousands of liters of such microorganisms and thus, to obtain large amounts of the desired product(s).

“Research and Discovery”: In Vitro Culture

44Regarding plant cell culture, several recent reviews bring a new light to in vitro culture, for investigation purposes as well as for its uses as a valuable platform for high-value metabolite production. Examples are scattered in the literature with in vitro cultures producing compounds of interest either using dedifferentiated cells from callus or undifferentiated cells from meristematic cambial cells. From the calli, systems of plant suspension cell cultures can be generated like for example for acteoside production from Scrophularia stiata, rosmarinic acid from Satureja khuzistanica, or carotenoid from Tagetes erecta.

45On the other hand, tissue cultures (i.e. hairy roots) can also be developed from already differentiated cells. All these types of culture are generally developed for a particular purpose, often very restricted to a given compound in a given plant, such as for camptothecin production by Ophiorrhiza species, Schisandra chinensis lignans production or boeravinone Y by Abronia nana. Several examples of cultures at a commercial scale have also been described validating its feasibility and scalability from lab-scale to large-scale (paclitaxel form Taxus spp. cultures, rosmarinic acid from Coleus blumei cultures, scopolamine from Duboisia spp. cultures to name only but a few).

46Nevertheless, if the literature provides us with some very well-described examples of such tasks, it remains to be seen if these techniques are universal. In other words, what has been described to be possible to obtain a “large scale” plant cell culture is not necessarily applicable to the next cell culture of a different plant, and a fortiori, of a different organ of the same plant species. What has been considered as a promising approach remains in some cases a challenge, as no experimental process has been developed—or published—with a general usage purpose. Thus, the perfectly described process to obtain stem-derived callus or leaf-derived callus producing anticancer phenolic compounds from Fagonia indica is only partially similar to the process to obtain callus from fruit pulp of varieties of apple producing high triterpenic acids or the process to obtain callus originating from seeds of Abronia nana, a desert plant found in North America to produce massive amount of boeravinone Y or even callus from Scrophularia striata for the production of acteoside. As seen above, many examples can be found in the literature, but the remaining question is how much the methodology varied from one example to the next in order to obtain such callus and then to obtain such cell suspensions producing the desired compound. Some general procedures for the establishment of dedifferentiated plant cell suspension cultures exist but with many specific adaptations in the function of species, organs of origins, and culture conditions. Probably because the authors concentrated mainly on the productivity and yield of the targeted compound and not on a larger picture applicable to a more general view of accessing and testing the chemical diversity of plants. If one considers the natural diversity lying in the plant species from our environment as a source of “new” chemicals, it would be wonderful to rely on a methodology universal enough to collect the biological material just once (or a very few times) and then, to rationalize the culture of the cells originating from the specific plant organ (leaves, stems, roots, etc.). The interest on these cell cultures is that the cells would be able to biosynthesize a large variety of compounds in quantities large enough to isolate and identify compounds with pharmacological activity and completely characterize them. At that stage, the culture size can be customized by expanding from several liters to several tens of liters of cell culture (hundreds if the initial results are promising and more biomass is needed to go on with testing). Finally, even modifications of culture conditions could work at enhancing chemical diversity or at least variations within the proportions of different secondary metabolites.

47The originality of our approach thus resides in using plant tissue and cell culture not for the production scale for which some limitations exist but to attempt facilitating the access to plant chemical diversity. With these perspectives, a repository associated with plant cell culture would be a valuable tool. And the versatility in terms of scaling the in vitro cultures would also allow bridging the gap between drug discovery and the first stages of development.

At the Development Stage: Systematic Inventories of Natural Products and Their Sources

48Classically, the approaches used for drug discovery—detailed above for some of them—are quite specific: trying to find a compound in a plant organ that has some specific activity against a particular enzyme, receptor, or pathway. On the contrary, a systematic “inventory” of the NP existing in living organisms, in plant parts for example, would be of great interest both for the drug discovery aspects as well as the development aspects, for the discovery aspects because it would allow a better use of the known natural chemical diversity and for the drug development aspects, because it would allow to change the sourcing of the NP keeping in mind how important the supply of the compound of natural origin is for a company.

49As shown for a few examples in Tables 2 – 4 which consist in a sampling of recently reported works on natural compounds, this “Systematism” is already used by a few groups who catalogued the chemical compounds in a given organ of a given plant, in a fungus, or in a microorganism. In such cases, an idea of the possible diversity of those sources is given. A compendium of some plant compositions had been done by I.A. Ross. Such inventory organized in a global database would greatly facilitate the access to the diversity of secondary metabolites of plants, for example. It would somewhat ease any strategy based on chemotaxonomy by describing better the filiations/relationships between the biosynthetical pathways in a different genus and by facilitating the access to some types of chemical skeletons in renewable naturally producing sources such as leaves or fruits. Furthermore, Table 4 indicates, in our view, the way the literature can be compiled from all the available sources to build a database based only on published articles describing one or several compounds from plant parts. In this line, the remarkable paper of reviews the available literature on the compounds from the dibenzylbutyrolactone lignan family and describes some 91 compounds of this chemical family from their origin in terms of plant species and plant parts.

50For many reasons, such a systematic inventory of plants chemical components related to the tissues and the species from which they have been extracted, would be of great use but could be difficult to complete, even with modern and fast analytical tools. Indeed, it is the completion of such a compendium that is the real challenge, and the experience of the few already existing NP databases exemplifies that challenge. For example the NAPRALERT experience (https://napralert.org) gathering data from more than 200,000 scientific papers is very informative: comprehensive coverage is claimed from 1975 to 2004 while only 20% of the global data is covered from 2005 due to budgetary constraints. Organisms, compounds, activities, or authors can be searched. In fact, the last decade has seen the development of several databases providing systematic collection of information that focuses on natural compounds themselves, offering the possibility of searching structure, source, and mechanisms of action of the searched compounds. For example, DEREP-NP is a database that compiles structural data. An interesting review from allows the comparison of fourteen of these databases focusing on NP, balancing their advantages and disadvantages. Among them, the updated version of a 2006 database SuperNatural II is a public resource (http://bioinformatics.charite.de/supernatural) with more than 325,500 natural compounds, offering 3D structure and conformers which seems to outperform many others. Another source of natural compounds is also the Greenpharma collection (www.greenpharma.com/products/compound-librairies/#GPNDB).

Industrial Scale Production: Synthetic Biology and Organic Syntheses

51The use of plant cell and organ culture for the production at the industrial scale of compounds with superior added value has been reported in various reviews. These reviews cited a large range of applications from the pharmaceutical area (suspension cells of Pacific yew in 75m3 stirred bioreactors delivering 500kg/year of paclitaxel) to the cosmetic and food industries like cell cultures of Malus domestica grown in 50 to 100 L production bioreactors. But still, it is acknowledged that some limitations exist: mainly the fact that time-consuming processes are involved, with possibly low titers, and the possibility of somaclonal variations appearing in the selected top producing cell lines. Several solutions to try to avoid these kinds of limitation can be assessed, but in our opinion, general strategies should consider other alternatives for the large industrial production scale depending on the kind of applications. For some specific NP of pharmacological interest like podophyllotoxin, artemisinin or plumbagin for example, a whole set of biotechnological approaches has been developed and described for the production at larger scale of these valuable compounds. But once more, these strategies are quite specific, driven only in one identified compound and its specific biosynthetical pathway.

Synthetic Biology

52As previously mentioned, one of the major requirements to this approach is to understand the pathways through which a particular compound is biosynthesized, thanks to the activity of a series of enzymes involved in a particular plant part. Within this last approach, the focus in plants is more on their capacity to synthetize unique scaffolds than on the end-products themselves. Indeed, the use of the recent integrative approaches based on “Omic” analyses (metabolomics, proteomics, transcriptomic, and genomics) can be of great value. Indeed, knowing the precursors and intermediates through the biochemical status of a tissue, identifying the key enzymes and the limiting steps of the pathways, monitoring indirectly the function of the genes involved in these pathways and their regulation will contribute to decipher the biosynthetic routes in planta. The relative ease at which one can now obtain large-scale data has facilitated the analyses at the level of the whole metabolic network. For example, large amounts of transcriptomic data are now easier to access as stated by, making possible the identification of multistep pathways by coexpression analyses or untargeted metabolomics. Furthermore, the discovery that genes linked to biosynthetic pathways are organized in clusters has opened new opportunities by adapting methodologies developed initially for microorganisms to plants like systematic cluster mining algorithms. reviewed recently the progresses made in the understanding of plant biosynthetic pathways with the integration of metabolomics and next-generation sequencing based on various families of compounds: for example, benzoisoquinoline and monoterpenoid indole alkaloids, cannabinoids, ginsenosides, or withanolides. They also emphasized the new insight that this area can bring in the field of synthesis of NP. They mention for example, the intriguing case of caffeine biosynthesis that evolved independently in several orders of eudicots: at least three metabolic pathways evolved separately coopting genes from different gene families illustrating how biosynthetic pathways can evolve with land plant diversification.

53After having identified the genes involved, the reconstitution of the biosynthetic pathways of interest can be realized thanks to novel DNA construction technologies. It can be realized in a foreign host which enables the increase of product yields. The choice of this host organism is key as the goal is to develop an efficient platform for heterologous gene expression. Microbial hosts are generally considered more amenable than plants to fermentation process. Among them, classical work horses like E. coli or S. cerevisiae, or newcomers like Bacillus subtilis and Pseudomonas putidaare can be cited. Another interesting example is the recent high-cell-density fermentation strategies developed for heterologous production in Pichia pastoris (W.-C. ). Then, basically, the strategy will consist in cloning the genes of the enzymes of the pathway that have been identified; constructing large plasmid (or family of plasmids) encoding for those enzymes; transfecting with the plasmid a microorganism that will be grown afterwards; and purifying the product. Several recent reviews detail how the technical advances in synthetic biology and multiplexed genome engineering allow for optimizing the design and synthesis of the pathways involved in NP production. Many such examples can be found such as for curcumin synthesis reconstitution in E. coli, polyunsaturated fatty acids production in the fungus Ashbya gossypii, α-amyrin, lupulones ou ginsenosides synthesis in S. cerevisiae, or the diversification of the carotenoid biosynthetic pathways. But probably the best example of economically feasible process is reported for the production of artemisin at an industrial scale.

54Alternatively, the developments in plant transformation and transfection technology offering rapid and scalable biosynthesis allow for considering more and more the use of plant-based expression platforms like Nicotiana or Arabidopsis spp.. Indeed they are considered genetically more flexible than the native plant sources and offer in some cases several advantages even over microbial hosts that can lack the endogenous biosynthetic precursors of these NP or intracellular compartments as endoplasmic reticulum related with the implementation of enzymes like cytochrome P450s.

55These advances in plant synthetic biology will increase the access to NP through new synthetic routes but will also allow the synthesis of new-to-nature molecules and so, expand the natural plant chemical diversity.

Organic Syntheses

56A way to analyze the total syntheses that have been recently produced in the literature is to use simple criteria in order to evaluate the feasibility of such approach in case of similar compounds finding their way to the clinic. We evaluated a set of recent publications dealing with “total synthesis” of NP according to the simple criteria: number of cycles in the compounds, number of carbons and heteroatoms—including sulfur—in those cycles and number of asymmetric carbons in these structures ( Table 6 ). In this nonexhaustive set of publications, it was decided not to consider peptides and peptide-derived macrocycles (about a dozen structures). The next observation was that there were a surprising high number of bacteria-derived compounds, a feature that we did not notice in our previous surveys ( Tables 2 – 4 ). Another parameter that allows for judging the feasibility and scalability of the processes is the yield and the number of steps. In that sense, most of those works are exquisitely delicate enterprises. The success of those publications in terms of tour de force is obvious, but they also allow for emphasizing the necessity to obtain such general synthetic routes, as most of those were used then to provide analogs to the desired NP in each publication.

57Some of those compounds are devoid of asymmetric carbons, rendering the synthesis ‘easier’, but still a challenge requiring several steps, with an overall poor yield. At the other end of the spectrum are compounds with a considerable number of asymmetric carbons, such as (+)-dimericbiscognienyne A with 12 asymmetric carbons, or namenamicin with 11 and/or with a high number of cycles, even if they were not always fused with each other. Indeed, a series of three furan-based cycles separated by alkyl carbon chains would not be a considerable difficulty to synthesize, depending on the decorations of those cycles that introduce notions of asymmetries and thus difficulties to perform.

58Those data, when compared to the ones gathered in Table 5, show that in these particular cases, the access by chemistry of all the possible optical isomers would be simply impossible. These observations cast some shadows on the possibility of using those synthetic routes at the industrial scale. On the other hand, the mastering of some steps, particularly the stereo-controlled ones, are key in the cases where alternative hemi-syntheses solutions are adopted from a most abundant intermediary (natural) compound. Finally, another point is certainly the growing numbers of synthetic routes that are explored, assessed, and validated to access some “common” features from those natural compounds. A review of this literature can be found in. Even if partial by essence, it shows the considerable number of routes that has been set up and that permits access to some of the main fused cycles found in compounds coming from different natural sources. Another review summarized the way spiroacetal can be accessed, another common feature of many natural compounds. This last point strongly emphasizes the common nature throughout the living world of the basic enzymatic systems aiming at producing secondary metabolites from the same fundamental bricks such as mevalonate or other isoprenoids.

59Nevertheless, it is also clear from that survey that chemistry is not, at the present time, the solution to the problem of scalability of NP productions to an industrial level, even if these compounds were extremely active on a given disease and even if a large panel of examples in which complete syntheses of NP are presented.

60As pointed out earlier in the present assay, at the research level and even at the level of exemplifications of chemical analogs of a given active, these approaches are necessary and important. Indeed, deciphering the various routes to some of those compounds might help design and simplify the overall structures, as it is the case in standard, organic chemistry-based, medicinal chemistry.

Conclusions

61For decades, the interplay between the search for “new” drugs and NP has been strong, to a point where some fear that the destruction of native forests, leading to a reduction of plant diversity would jeopardize our finding of new cures for old and new diseases. The present essay aimed to offer a global overview of the extent of the known chemical diversity, its access, and its use. Several approaches to chemical diversity were also discussed maximizing, in our view, the possibilities of finding useful compounds for human unmet medical needs.

62As illustrated, plant natural chemical diversity is indeed immense. And the knowledge we gathered on plants is only the tip of the iceberg as exemplified in IA Ross’s books, in which he gathered all the chemical components found in some 40 plants and their many different components. And this knowledge is certainly scattered all over the world. A unifying work should be done, under a simple format, that could be like the one presented in Table 3 and completed by following the example of. This kind of tool would incredibly ease the access to plant natural chemical diversity and should ideally be comprehensive, organized and include data from worldwide plant species, from past to recent studies. Such a globalized database could furthermore be integrated to other ones like genomic, phylogenic, species occurrence, biosynthetic pathway, biological activity, or chemical classification allowing researchers to mine the resources and correlate the information, hence empowering all kind of research studies. This trend has been emphasized by several authors in their recent reviews stating that drug discovery from plants requires multidisciplinary approaches. Experiences from the past tell us how important it is, for drug discovery purposes, to access this wide diversity lying in the Plant kingdom, especially because it may be shrinking due to the rapid alterations of the biosphere. In order to fully access the whole chemical diversity without jeopardizing plant biodiversity, alternative ways to collect and store plant tissues can be explored, as for example the use of in vitro culture techniques allowing a renewable and sustainable access to plant chemical diversity. As the final purpose is giving access to workable quantities of therapeutic compound(s), we suggested that the advances in synthetic biology coupled with genomics and bioinformatics can pave the way to possible future strategies of productions of the compounds originating from this diversity. But the chemical diversity in the scaffolds of plant natural compounds is so wide that there is still some space from different strategies for large-scale production: from organic total synthesis for the simpler scaffolds like ephedrine or metformin that are able to be synthetized in few steps, that is to say, at a reasonable cost or, at the other end of the spectrum, heterologous (plant)? production for compounds with more complex scaffolds like taxanes and multistep biosynthesis, and in between even hybrids (multihosts)? semisynthetic strategies can be imagined and developed.

Author Contributions

63EL and JB wrote the review with the help of PD (modelization) and OR (chemistry).

Conflict of Interest

64The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 495

1.
Abdallah I. I. Pramastya H. van Merkerk R. Sukrasno Quax W. J. (2019 ). Metabolic Engineering of Bacillus subtilis Toward Taxadiene Biosynthesis as the First Committed Step for Taxol Production. Front. Microbiol. 10, 218.
Not in our library10.3389/fmicb.2019.00218
2.
Abed S. A. Sirat H. M. Taher M. (2016 ). Tyrosinase inhibition, anti-acetylcholinesterase, and antimicrobial activities of the phytochemicals from Gynotroches axillaris Blume. Pakistan J. Pharm. Sci. 29, 2071–2078.
Not in our library
3.
Acharyya R. K. Nanda S. (2018 ). Asymmetric total synthesis of naturally occurring spirocyclic tetranorsesquiterpenoid lanceolactone A. Org. Biomolec. Chem. 16, 5027–5035.
Not in our library10.1039/c8ob01328d
4.
Ademosun A. O. Oboh G. Passamonti S. Tramer F. Ziberna L. Boligon A. A. (2015 ). Inhibition of metalloproteinase and proteasome activities in colon cancer cells by citrus peel extracts. J. Basic Clin. Physiol. Pharmacol. 26, 471–477.
Not in our library10.1515/jbcpp-2013-0127
5.
Afifi A. H. Kagiyama I. El-Desoky A. H. Kato H. Mangindaan R. E. P. Voogd N. J. (2017 ). Sulawesins A-C, Furanosesterterpene Tetronic Acids That Inhibit USP7, from a Psammocinia sp. Marine Sponge. J. Natural Prod. 80, 2045–2050.
Not in our library10.1021/acs.jnatprod.7b00184
6.
Ahoua A. R. C. Monteillier A. Borlat F. Ciclet O. Marcourt L. Nejad Ebrahimi S. (2018 ). Anti-inflammatory and Quinone Reductase-Inducing Compounds from Beilschmiedia mannii. Planta Med. 85, 379–384.
Not in our library10.1055/a-0798-3155
7.
Ajibola C. F. Eleyinmi A. F. Aluko R. E. (2011 ). Kinetics of the Inhibition of Renin and Angiotensin I Converting Enzyme by Polar and Non-polar Polyphenolic Extracts of Vernonia Amygdalina and Gongronema Latifolium Leaves. Plant Foods Hum. Nutr. 66, 320–327.
Not in our library10.1007/s11130-011-0257-x
8.
Akbari F. Arminian A. Kahrizi D. Fazeli A. Ghaheri M. (2018 ). Effect of nitrogen sources on gene expression of Stevia rebaudiana (Bertoni) under in vitro conditions. Cell. Mol. Biol. (Noisy-le-grand) 64, 11–16.
Not in our library10.14715/cmb/2018.64.2.3
9.
Alchin D. R. (2014 ). Ingenol Mebutate: A Succinct Review of a Succinct Therapy. Dermatol. Ther. (Heidelb) 4, 157–164.
Not in our library10.1007/s13555-014-0061-2
10.
Alcock L. J. Norris M. D. Perkins M. V. (2018 ). Total synthesis and structural elucidation of spongosoritin A. Org. Biomolec. Chem. 16, 1351–1358.
Not in our library10.1039/c7ob03150e
11.
Ali T. Inagaki M. Chai H.-B. Wieboldt T. Rapplye C. Rakotondraibe L. H. (2017 ). Halogenated Compounds from Directed Fermentation of Penicillium concentricum, an Endophytic Fungus of the Liverwort Trichocolea tomentella. J. Natural Prod. 80, 1397–1403.
Not in our library10.1021/acs.jnatprod.6b01069
12.
Al-Khdhairawi A. A. Q. Krishnan P. Mai C.-W. Chung F. F.-L. Leong C.-O. Yong K.-T. (2017 ). A Bis-benzopyrroloisoquinoline Alkaloid Incorporating a Cyclobutane Core and a Chlorophenanthroindolizidine Alkaloid with Cytotoxic Activity from Ficus fistulosa var. tengerensis. J. Natural Prod. 80, 2734–2740.
Not in our library10.1021/acs.jnatprod.7b00500
13.
Allen J. M. Folk R. A. Soltis P. S. Soltis D. E. Guralnick R. P. (2019 ). Biodiversity synthesis across the green branches of the tree of life. Nat. Plants 5, 11–13.
Not in our library10.1038/s41477-018-0322-7
14.
Almohseni H. A. A. Al Mamari H. H. Valade A. Sintim H. O. Hodgson D. M. (2018 ). Alkene protection against acid using a bromide substituent: application in a total synthesis of (-)-6,7-dideoxysqualestatin H5. Chem. Commun. (Cambridge England) 54, 5354–5356.
Not in our library10.1039/c8cc02690d
15.
Amagata T. (2010 ). Missasigned Structures: Case Examples from the Past Decade. Compr. Natural Products II, eds Mander L. Liu H.-W. Oxford: Elsevier,. 581–621.
Not in our library10.1016/b978-008045382-8.00053-8
16.
Apel C. Bignon J. Garcia-Alvarez M. C. Ciccone S. Clerc P. Grondin I. (2018 ). N-myristoyltransferases inhibitory activity of ellagitannins from Terminalia bentzoë (L.) L. f. subsp. bentzoë. Fitoterapia 131, 91–95.
Not in our library10.1016/j.fitote.2018.10.014
17.
Appelhagen I. Wulff-Vester A. K. Wendell M. Hvoslef-Eide A.-K. Russell J. Oertel A. (2018 ). Colour bio-factories: Towards scale-up production of anthocyanins in plant cell cultures. Metab. Eng. 48, 218–232.
Not in our library10.1016/j.ymben.2018.06.004
18.
Asano T. Sudo H. Yamazaki M. Saito K. (2009 ). Camptothecin production by in vitro cultures and plant regeneration in Ophiorrhiza species. Methods Mol. Biol. (Clifton N.J.) 547, 337–345.
Not in our library10.1007/978-1-60327-287-2_27
19.
Discovery and resupply of pharmacologically active plant-derived natural products: A review · 2015
No notice
20.
Au T. K. Lam T. L. Ng T. B. Fong W. P. Wan D. C. (2001 ). A comparison of HIV-1 integrase inhibition by aqueous and methanol extracts of Chinese medicinal herbs. Life Sci. 68, 1687–1694.
Not in our library10.1016/s0024-3205(01)00945-6
21.
Austin C. Stewart D. Allwood J. W. McDougall G. J. (2018 ). Extracts from the edible seaweed, Ascophyllum nodosum, inhibit lipase activity in vitro: Contributions of phenolic and polysaccharide components. Food Funct. 9, 502–510.
Not in our library10.1039/c7fo01690e
22.
Awan A. R. Shaw W. M. Ellis T. (2016 ). Biosynthesis of therapeutic natural products using synthetic biology. Adv. Drug Deliv. Rev. 105, 96–106.
Not in our library10.1016/j.addr.2016.04.010
23.
Badral D. Odonbayar B. Murata T. Munkhjargal T. Tuvshintulga B. Igarashi I. (2017 ). Flavonoid and Galloyl Glycosides Isolated from Saxifraga spinulosa and Their Antioxidative and Inhibitory Activities against Species That Cause Piroplasmosis. J. Natural Prod. 80, 2416–2423.
Not in our library10.1021/acs.jnatprod.7b00142
24.
Bailey C. J. (2017 ). Metformin: historical overview. Diabetologia 60, 1566–1576.
Not in our library10.1007/s00125-017-4318-z
25.
Baker G. H. Dorgan R. J. Everett J. R. Hood J. D. Poulton M. E. (1990 ). A novel series of milbemycin antibiotics from Streptomyces strain E225. II. Isolation, characterization, structure elucidation and solution conformations. J. Antibiot. 43, 1069–1076.
Not in our library10.7164/antibiotics.43.1069
26.
Balcells S. Haughey M. B. Walker J. C. L. Josa-Cullere L. Towers C. Donohoe T. J. (2018 ). Asymmetric Total Synthesis of (-)-(3 R)-Inthomycin C. Org. Lett. 20, 3583–3586.
Not in our library10.1021/acs.orglett.8b01370
27.
Super Natural II—a database of natural products · 2014
No notice
28.
Bao M.-F. Zeng C.-X. Liu Y.-P. Zhang B.-J. Ni L. Luo X.-D. (2017 ). Indole Alkaloids from Hunteria zeylanica. J. Natural Prod. 80, 790–797.
Not in our library10.1021/acs.jnatprod.5b01035
29.
Batista A. N. L. dos Santos-Pinto J. R. Batista J. M. Souza-Moreira T. M. Santoni M. M. Zanelli C. F. (2017 ). The Combined Use of Proteomics and Transcriptomics Reveals a Complex Secondary Metabolite Network in Peperomia obtusifolia. J. Natural Prod. 80, 1275–1286.
Not in our library10.1021/acs.jnatprod.6b00827
30.
Bauer M. R. Mackey M. D. (2019 ). Electrostatic Complementarity as a Fast and Effective Tool to Optimize Binding and Selectivity of Protein-Ligand Complexes. J. Med. Chem. 62, 3036–3050.
Not in our library10.1021/acs.jmedchem.8b01925
31.
Bautista E. Ortiz-Pastrana N. Pastor-Palacios G. Montoya-Contreras A. Toscano R. A. Morales-Jimenez J. (2017 ). neo-Clerodane Diterpenoids from Salvia polystachya Stimulate the Expression of Extracellular Matrix Components in Human Dermal Fibroblasts. J. Natural Prod. 80, 3003–3009.
Not in our library10.1021/acs.jnatprod.7b00591
32.
Beaufay C. Ledoux A. Jansen O. Bordignon A. Zhao S. Teijaro C. N. (2018 ). In vivo Antimalarial and Antitrypanosomal Activity of Strychnogucine B, a Bisindole Alkaloid from Strychnos icaja. Planta Med. 84, 881–885.
Not in our library10.1055/a-0644-2723
33.
Bednarek P. Osbourn A. (2009 ). Plant-microbe interactions: chemical diversity in plant defense. Sci. (New York N.Y.) 324, 746–748.
Not in our library10.1126/science.1171661
34.
Bedut S. Seminatore-Nole C. Lamamy V. Caignard S. Boutin J. A. Nosjean O. (2016 ). High-throughput drug profiling with voltage- and calcium-sensitive fluorescent probes in human iPSC-derived cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 311, H44–H53.
Not in our library10.1152/ajpheart.00793.2015
35.
Bemis G. W. Murcko M. A. (1996 ). The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 39, 2887–2893.
Not in our library10.1021/jm9602928
36.
Callus culture development of two varieties of Tagetes erecta and carotenoid production · 2014
Not checked
37.
Berboucha M. Ayouni K. Atmani D. Atmani D. Benboubetra M. (2010 ). Kinetic study on the inhibition of xanthine oxidase by extracts from two selected Algerian plants traditionally used for the treatment of inflammatory diseases. J. Med. Food 13, 896–904.
Not in our library10.1089/jmf.2009.0164
38.
Bisio A. Mieri M. Milella L. Schito A. M. Parricchi A. Russo D. (2017 ). Antibacterial and Hypoglycemic Diterpenoids from Salvia chamaedryoides. J. Natural Prod. 80, 503–514.
Not in our library10.1021/acs.jnatprod.6b01053
39.
Bjerketorp J. Levenfors J. J. Sahlberg C. Nord C. L. Andersson P. F. Guss B. (2017 ). Antibacterial 3,6-Disubstituted 4-Hydroxy-5,6-dihydro-2H-pyran-2-ones from Serratia plymuthica MF371-2. J. Natural Prod. 80, 2997–3002.
Not in our library10.1021/acs.jnatprod.7b00565
40.
Blitz M. Heinze R. C. Harms K. Koert U. (2019 ). Total Synthesis of (+)-Nivetetracyclate A. Org. Lett. 21, 785–788.
Not in our library10.1021/acs.orglett.8b04044
41.
Bodle C. R. Mackie D. I. Hayes M. P. Schamp J. H. Miller M. R. Henry M. D. (2017 ). Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines. J. Natural Prod. 80, 1992–2000.
Not in our library10.1021/acs.jnatprod.7b00112
42.
Borra S. Lapinskaite R. Kempthorne C. Liscombe D. McNulty J. Hudlicky T. (2018 ). Isolation, Synthesis, and Semisynthesis of Amaryllidaceae Constituents from Narcissus and Galanthus sp. De Novo Total Synthesis of 2- epi-Narciclasine. J. Natural Prod. 81, 1451–1459.
Not in our library10.1021/acs.jnatprod.8b00218
43.
Boss C. Hazemann J. Kimmerlin T. Korff M. Lüthi U. Peter O. (2017 ). The Screening Compound Collection: A Key Asset for Drug Discovery. Chimia 71, 667–677.
Not in our library10.2533/chimia.2017.667
44.
Boumaraf M. Carbone M. Ciavatta M. L. Benyahia S. Ameddah S. Menad A. (2017 ). Exploring the Bioactive Terpenoid Content of an Algerian Plant of the Genus Pulicaria: The ent-Series of Asteriscunolides. J. Natural Prod. 80, 82–89.
Not in our library10.1021/acs.jnatprod.6b00717
45.
Bousserouel H. Litaudon M. Morleo B. Martin M.-T. Thoison O. Nosjean O. (2005 ). New biologically active linear triterpenes from the bark of three new-caledonian Cupaniopsis species. Tetrahedron 61, 845–851.
Not in our library10.1016/j.tet.2004.11.036
46.
Boutin J. A. Nosjean O. Ferry G. (2018 ). “On the Organization of a Drug Discovery Platform,” in Drug Discovery - Concepts to Market. Ed. Bobbarala V. London, UK InTechOpen Limited.
Not in our library10.5772/intechopen.73170
47.
Bouvier F. Rahier A. Camara B. (2005 ). Biogenesis, molecular regulation and function of plant isoprenoids. Prog. Lipid Res. 44, 357–429.
Not in our library10.1016/j.plipres.2005.09.003
48.
Brana A. F. Sarmiento-Vizcaino A. Perez-Victoria I. Otero L. Fernandez J. Palacios J. J. (2017 ). Branimycins B and C, Antibiotics Produced by the Abyssal Actinobacterium Pseudonocardia carboxydivorans M-227. J. Natural Prod. 80, 569–573.
Not in our library10.1021/acs.jnatprod.6b01107
49.
Breitling R. Takano E. (2016 ). Synthetic Biology of Natural Products. Cold Spring Harbor Perspect. Biol. 8 a023994,
Not in our library10.1101/cshperspect.a023994
50.
Breton R. C. Reynolds W. F. (2013 ). Using NMR to identify and characterize natural products. Nat. Prod. Rep. 30, 501–524.
Not in our library10.1039/c2np20104f
51.
Bunteang S. Chanakul W. Hongthong S. Kuhakarn C. Chintakovid W. Sungchawek N. (2018 ). Anti-HIV Activity of Alkaloids from Dasymaschalon echinatum. Natural Prod. Commun. 13, 29–32.
Not in our library10.1177/1934578x1801300110
52.
Burson R. Moran K. J. (2015 ). Gliflozins. Home Healthc. Now 33, 281.
Not in our library10.1097/nhh.0000000000000238
53.
Camero C. M. Vassallo A. Leo M. Temraz A. Tommasi N. Braca A. (2018 ). Limonoids from Aphanamixis polystachya Leaves and Their Interaction with Hsp90. Planta Med. 84, 964–970.
Not in our library10.1055/a-0624-9538
54.
Campos P.-E. Wolfender J.-L. Queiroz E. F. Marcourt L. Al-Mourabit A. Frederich M. (2017 ). Unguiculin A and Ptilomycalins E-H, Antimalarial Guanidine Alkaloids from the Marine Sponge Monanchora unguiculata. J. Natural Prod. 80, 1404–1410.
Not in our library10.1021/acs.jnatprod.6b01079
55.
Cao Y. Zhao M. Zhu Y. Zhu Z.-H. Oberer L. Duan J.-A. (2017 ). Diselaginellin B, an Unusual Dimeric Molecule from Selaginella pulvinata, Inhibited Metastasis and Induced Apoptosis of SMMC-7721 Human Hepatocellular Carcinoma Cells. J. Natural Prod. 80, 3151–3158.
Not in our library10.1021/acs.jnatprod.7b00404
56.
Carbonell P. Currin A. Jervis A. J. Rattray N. J. W. Swainston N. Yan C. (2016 ). Bioinformatics for the synthetic biology of natural products: integrating across the Design-Build-Test cycle. Nat. Prod. Rep. 33, 925–932.
Not in our library10.1039/c6np00018e
57.
Carpentier C. Queiroz E. F. Marcourt L. Wolfender J.-L. Azelmat J. Grenier D. (2017 ). Dibenzofurans and Pseudodepsidones from the Lichen Stereocaulon paschale Collected in Northern Quebec. J. Natural Prod. 80, 210–214.
Not in our library10.1021/acs.jnatprod.6b00831
58.
Exopolysaccharides from Marine and Marine Extremophilic Bacteria: Structures, Properties, Ecological Roles and Applications · 2018
No notice
59.
Catteau L. Reichmann N. Olson J. Pinho M. Nizet V. van Bambeke F. (2017 ). Synergy between Ursolic and Oleanolic Acids from Vitellaria paradoxa Leaf Extract and β-Lactams against Methicillin-Resistant Staphylococcus aureus: In Vitro and In Vivo Activity and Underlying Mechanisms. Molecules 22, 2245.
Not in our library10.3390/molecules22122245
60.
Chakka N. Andrews K. L. Berry L. M. Bregman H. Gunaydin H. Huang L. (2017 ). Applications of parallel synthetic lead hopping and pharmacophore-based virtual screening in the discovery of efficient glycine receptor potentiators. Eur. J. Med. Chem. 137, 63–75.
Not in our library10.1016/j.ejmech.2017.05.036
61.
Chang J.-C. Hsiao G. Lin R.-K. Kuo Y.-H. Ju Y.-M. Lee T.-H. (2017 ). Bioactive Constituents from the Termite Nest-Derived Medicinal Fungus Xylaria nigripes. J. Natural Prod. 80, 38–44.
Not in our library10.1021/acs.jnatprod.6b00249
62.
Chapman L. M. Beck J. C. Lacker C. R. Wu L. Reisman S. E. (2018 ). Evolution of a Strategy for the Enantioselective Total Synthesis of (+)-Psiguadial B. J. Org. Chem. 83, 6066–6085.
Not in our library10.1021/acs.joc.8b00728
63.
Cheallaigh A. N. Mansell D. J. Toogood H. S. Tait S. Lygidakis A. Scrutton N. S. (2018 ). Chemoenzymatic Synthesis of the Intermediates in the Peppermint Monoterpenoid Biosynthetic Pathway. J. Natural Prod. 81, 1546–1552.
Not in our library10.1021/acs.jnatprod.7b01026
64.
Chen L. Niu S.-B. Li L. Ding G. Yu M. Zhang G.-S. (2017 ). Trichoderpyrone, a Unique Polyketide Hybrid with a Cyclopentenone-Pyrone Skeleton from the Plant Endophytic Fungus Trichoderma gamsii. J. Natural Prod. 80, 1944–1947.
Not in our library10.1021/acs.jnatprod.7b00190
65.
Chen M. Shen N.-X. Chen Z.-Q. Zhang F.-M. Chen Y. (2017 ). Penicilones A-D, Anti-MRSA Azaphilones from the Marine-Derived Fungus Penicillium janthinellum HK1-6. J. Natural Prod. 80, 1081–1086.
Not in our library10.1021/acs.jnatprod.6b01179
66.
Chen M.-C. Cho T.-Y. Kuo Y.-H. Lee T.-H. (2017 ). Meroterpenoids from a Medicinal Fungus Antrodia cinnamomea. J. Natural Prod. 80, 2439–2446.
Not in our library10.1021/acs.jnatprod.7b00223
67.
Cheng B. Volpin G. Morstein J. Trauner D. (2018 ). Total Synthesis of (+/-)-Exotine B. Org. Lett. 20, 4358–4361.
Not in our library10.1021/acs.orglett.8b01817
68.
Cheng Y.-B. Liu F.-J. Wang C.-H. Hwang T.-L. Tsai Y.-F. Yen C.-H. (2018 ). Bioactive Triterpenoids from the Leaves and Twigs of Lithocarpus litseifolius and L. corneus. Planta Med. 84, 49–58.
Not in our library10.1055/s-0043-113826
69.
Chianese G. Silber J. Luciano P. Merten C. Erpenbeck D. Topaloglu B. (2017 ). Antiprotozoal Linear Furanosesterterpenoids from the Marine Sponge Ircinia oros. J. Natural Prod. 80, 2566–2571.
Not in our library10.1021/acs.jnatprod.7b00543
70.
Cho N. Ransom T. T. Sigmund J. Tran T. Cichewicz R. H. Goetz M. (2017 ). Growth Inhibition of Colon Cancer and Melanoma Cells by Versiol Derivatives from a Paraconiothyrium Species. J. Natural Prod. 80, 2037–2044.
Not in our library10.1021/acs.jnatprod.7b00170
71.
Protocols for RecET‐based markerless gene knockout and integration to express heterologous biosynthetic gene clusters in Pseudomonas putida · 2020
Not checked
72.
Clemons P. A. Wilson J. A. Dančík V. Muller S. Carrinski H. A. Wagner B. K. (2011 ). Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections. Proc. Natl. Acad. Sci. U.S.A. 108, 6817–6822.
Not in our library10.1073/pnas.1015024108
73.
Columba-Palomares M. F. M. C. Villareal D. M. Acevedo Quiroz M. C. M. E. Marquina Bahena M. C. S. Álvarez Berber D. L. Rodríguez-López D. V. (2015 ). Anti-inflammatory and cytotoxic activities of Bursera copallifera. Phcog. Mag. 11, 322.
Not in our library10.4103/0973-1296.166067
74.
Correia A. F. Segovia J. F. O. Gonçalves M. C. A. Oliveira V. L. Silveira D. Carvalho J. C. T. (2008 ). Amazonian plant crude extract screening for activity against multidrug-resistant bacteria. Eur. Rev. Med. Pharmacol. Sci. 12, 369–380.
Not in our library
75.
Cragg G. M. Newman D. J. Snader K. M. (1997 ). Natural products in drug discovery and development. J. Natural Prod. 60, 52–60.
Not in our library10.1021/np9604893
76.
Da Silva P. P. J. Meijer L. (2012 ). Recherche de substances naturelles à activité thérapeutique: Pierre Potier, (1934-2006). Med. Sci.: M/S 28, 534–542.
Not in our library10.1051/medsci/2012285020
77.
Dai J. Wang G. Li W. Zhang L. Yang J. Zhao X. (2012 ). High-Throughput Screening for Anti–Influenza A Virus Drugs and Study of the Mechanism of Procyanidin on Influenza A Virus–Induced Autophagy. J. Biomol. Screen 17, 605–617.
Not in our library10.1177/1087057111435236
78.
Dai Z. Wang B. Liu Y. Shi M. Wang D. Zhang X. (2014 ). Producing aglycons of ginsenosides in bakers’ yeast. Sci. Rep. 4, 3698.
Not in our library10.1038/srep03698
79.
Dang P. H. Nguyen H. X. Duong T. T. T. Tran T. K. T. Nguyen P. T. Vu T. K. T. (2017 a). alpha-Glucosidase Inhibitory and Cytotoxic Taxane Diterpenoids from the Stem Bark of Taxus wallichiana. J. Natural Prod. 80, 1087–1095.
Not in our library10.1021/acs.jnatprod.7b00006
80.
Dang P. H. Nguyen H. X. Nguyen H. H. T. Vo T. D. Le T. H. Phan T. H. N. (2017 b). Lignans from the Roots of Taxus wallichiana and Their alpha-Glucosidase Inhibitory Activities. J. Natural Prod. 80, 1876–1882.
Not in our library10.1021/acs.jnatprod.7b00171
81.
Davison E. K. Hume P. A. Sperry J. (2018 ). Total Synthesis of an Isatis indigotica-Derived Alkaloid Using a Biomimetic Thio-Diels-Alder Reaction. Org. Lett. 20, 3545–3548.
Not in our library10.1021/acs.orglett.8b01321
82.
Dethe D. H. Dherange B. D. (2018 ). Total Synthesis of Adunctin B. J. Org. Chem. 83, 3392–3396.
Not in our library10.1021/acs.joc.8b00015
83.
Deyou T. Marco M. Heydenreich M. Pan F. Gruhonjic A. Fitzpatrick P. A. (2017 ). Isoflavones and Rotenoids from the Leaves of Millettia oblata ssp. teitensis. J. Natural Prod. 80, 2060–2066.
Not in our library10.1021/acs.jnatprod.7b00255
84.
Dissanayake A. A. Ameen B. A. H. Nair M. G. (2017 ). Lipid Peroxidation and Cyclooxygenase Enzyme Inhibitory Compounds from Prangos haussknechtii. J. Natural Prod. 80, 2472–2477.
Not in our library10.1021/acs.jnatprod.7b00322
85.
Do Q. T. Medina-Franco J. L. Scior T. Bernard P. (2015 ). How to Valorize Biodiversity? Let’s Go Hashing, Extracting, Filtering, Mining, Fishing. Planta Med. 81, 436–449.
Not in our library10.1055/s-0034-1396314
86.
Do L. T. M. Aree T. Siripong P. Vo N. T. Nguyen T. T. A. Nguyen P. K. P. (2018 ). Cytotoxic Flavones from the Stem Bark of Bougainvillea spectabilis Willd. Planta Med. 84, 129–134.
Not in our library10.1055/s-0043-118102
87.
Dong S. Li B. Dai W. Wang D. Qin Y. Zhang M. (2017 ). Sesqui- and Diterpenoids from the Radix of Curcuma aromatica. J. Natural Prod. 80, 3093–3102.
Not in our library10.1021/acs.jnatprod.6b01100
88.
Du Y. Pearce K. C. Dai Y. Krai P. Dalal S. Cassera M. B. (2017 ). Antiplasmodial Sesquiterpenoid Lactones from Trichospira verticillata: Structure Elucidation by Spectroscopic Methods and Comparison of Experimental and Calculated ECD Data. J. Natural Prod. 80, 1639–1647.
Not in our library10.1021/acs.jnatprod.7b00247
89.
Duan Y.-T. Zhang J. Lao Y.-Z. Tan H.-S. Ye Y.-S. Yang X.-W. (2018 ). Spirocyclic polycyclic polyprenylated acylphloroglucinols from the ethyl acetate fraction of Hypericum henryi. Tetrahedron Lett. 59, 4067–4072.
Not in our library10.1016/j.tetlet.2018.09.071
90.
Dufresne C. (2000 ). The planning and establishment of a sample preparation laboratory for drug discovery. J. Autom. Methods Manage. Chem. 22, 175–179.
Not in our library10.1155/s1463924600000316
91.
Eibl R. Meier P. Stutz I. Schildberger D. Hühn T. Eibl D. (2018 ). Plant cell culture technology in the cosmetics and food industries: current state and future trends. Appl. Microbiol. Biotechnol. 102, 8661–8675.
Not in our library10.1007/s00253-018-9279-8
92.
El-Desoky A. H. Kato H. Kagiyama I. Hitora Y. Losung F. Mangindaan R. E. P. (2017 ). Ceylonins A-F, Spongian Diterpene Derivatives That Inhibit RANKL-Induced Formation of Multinuclear Osteoclasts, from the Marine Sponge Spongia ceylonensis. J. Natural Prod. 80, 90–95.
Not in our library10.1021/acs.jnatprod.6b00725
93.
El-Elimat T. Figueroa M. Ehrmann B. M. Cech N. B. Pearce C. J. Oberlies N. H. (2013 ). High-resolution MS, MS/MS, and UV database of fungal secondary metabolites as a dereplication protocol for bioactive natural products. J. Natural Prod. 76, 1709–1716.
Not in our library10.1021/np4004307
94.
Endo Y. Kasahara T. Harada K. Kubo M. Etoh T. Ishibashi M. (2017 ). Sucupiranins A-L, Furanocassane Diterpenoids from the Seeds of Bowdichia virgilioides. J. Natural Prod. 80, 3120–3127.
Not in our library10.1021/acs.jnatprod.7b00249
95.
Erlanson D. A. Fesik S. W. Hubbard R. E. Jahnke W. Jhoti H. (2016 ). Twenty years on: The impact of fragments on drug discovery. Nat. Rev. Drug Discovery 15, 605–619.
Not in our library10.1038/nrd.2016.109
96.
Esposito M. Nothias L.-F. Retailleau P. Costa J. Roussi F. Neyts J. (2017 ). Isolation of Premyrsinane, Myrsinane, and Tigliane Diterpenoids from Euphorbia pithyusa Using a Chikungunya Virus Cell-Based Assay and Analogue Annotation by Molecular Networking. J. Natural Prod. 80, 2051–2059.
Not in our library10.1021/acs.jnatprod.7b00233
97.
Fan Y.-Y. Xu J.-B. Liu H.-C. Gan L.-S. Ding J. Yue J.-M. (2017 ). Cephanolides A-J, Cephalotane-Type Diterpenoids from Cephalotaxus sinensis. J. Natural Prod. 80, 3159–3166.
Not in our library10.1021/acs.jnatprod.7b00412
98.
Feher M. Schmidt J. M. (2003 ). Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci. 43, 218–227.
Not in our library10.1021/ci0200467
99.
Feng Z.-L. Zhang L.-L. Zheng Y.-D. Liu Q.-Y. Liu J.-X. Feng L. (2017 ). Norditerpenoids and Dinorditerpenoids from the Seeds of Podocarpus nagi as Cytotoxic Agents and Autophagy Inducers. J. Natural Prod. 80, 2110–2117.
Not in our library10.1021/acs.jnatprod.7b00347
100.
Fernie A. R. (2007 ). The future of metabolic phytochemistry: larger numbers of metabolites, higher resolution, greater understanding. Phytochemistry 68, 2861–2880.
Not in our library10.1016/j.phytochem.2007.07.010
101.
Ferrer S. Echavarren A. M. (2018 ). Total Synthesis of Repraesentin F and Configuration Reassignment by a Gold(I)-Catalyzed Cyclization Cascade. Org. Lett. 20, 5784–5788.
Not in our library10.1021/acs.orglett.8b02478
102.
Figueroa-López A. M. Cordero-Ramírez J. D. Quiroz-Figueroa F. R. Maldonado-Mendoza I. E. (2014 ). A high-throughput screening assay to identify bacterial antagonists against Fusarium verticillioides. J. Basic Microbiol. 54, S125–S133.
Not in our library10.1002/jobm.201200594
103.
Firn R.D. Jones C. G. (2003 ). Natural products ? a simple model to explain chemical diversity. Nat. Prod. Rep. 20, 382.
Not in our library10.1039/b208815k
104.
Flores-Bocanegra L. Gonzalez-Andrade M. Bye R. Linares E. Mata R. (2017 ). alpha-Glucosidase Inhibitors from Salvia circinata. J. Natural Prod. 80, 1584–1593.
Not in our library10.1021/acs.jnatprod.7b00155
105.
Flores-Giubi M. E. Duran-Pena M. J. Botubol-Ares J. M. Escobar-Montano F. Zorrilla D. Macias-Sanchez A. J. (2017 ). Gaditanone, a Diterpenoid Based on an Unprecedented Carbon Skeleton Isolated from Euphorbia gaditana. J. Natural Prod. 80, 2161–2165.
Not in our library10.1021/acs.jnatprod.7b00332
106.
Fois B. Bianco G. Sonar V. P. Distinto S. Maccioni E. Meleddu R. (2017 ). Phenylpropenoids from Bupleurum fruticosum as Anti-Human Rhinovirus Species A Selective Capsid Binders. J. Natural Prod. 80, 2799–2806.
Not in our library10.1021/acs.jnatprod.7b00648
107.
A new synthetic biology approach allows transfer of an entire metabolic pathway from a medicinal plant to a biomass crop · 2016
No notice
108.
Galappathie S. Edwards D. J. Elliott A. G. Cooper M. A. Palombo E. A. Butler M. S. (2017 ). Antibacterial Nerol Cinnamates from the Australian Plant Eremophila longifolia. J. Natural Prod. 80, 1178–1181.
Not in our library10.1021/acs.jnatprod.6b00888
109.
Gally J.-M. Bourg S. Do Q.-T. Aci-Sèche S. Bonnet P. (2017 ). VSPrep: A General KNIME Workflow for the Preparation of Molecules for Virtual Screening. Mol. Inform. 36, 10.1002.
Not in our library10.1002/minf.201700023
110.
Gan P. Pitzen J. Qu P. Snyder S. A. (2018 ). Total Synthesis of the Caged Indole Alkaloid Arboridinine Enabled by aza-Prins and Metal-Mediated Cyclizations. J. Am. Chem. Soc. 140, 919–925.
Not in our library10.1021/jacs.7b07724
111.
Gao J. Aisa H. A. (2017 ). Terpenoids from Euphorbia soongarica and Their Multidrug Resistance Reversal Activity. J. Natural Prod. 80, 1767–1775.
Not in our library10.1021/acs.jnatprod.6b01099
112.
Gao E. Zhou Z.-Q. Zou J. Yu Y. Feng X.-L. Chen G.-D. (2017 ). Bioactive Asarone-Derived Phenylpropanoids from the Rhizome of Acorus tatarinowii Schott. J. Natural Prod. 80, 2923–2929.
Not in our library10.1021/acs.jnatprod.7b00457
113.
Geng H. Huang P.-Q. (2019 ). Rapid Generation of Molecular Complexity by Chemical Synthesis: Highly Efficient Total Synthesis of Hexacyclic Alkaloid (-)-Chaetominine and Its Biosynthetic Implications. Chem. Rec. (New York N.Y.) 19, 523–533.
Not in our library10.1002/tcr.201800079
114.
Geng C.-A. Huang X.-Y. Ma Y.-B. Hou B. Li T.-Z. Zhang X.-M. (2017 ). (+/-)-Uncarilins A and B, Dimeric Isoechinulin-Type Alkaloids from Uncaria rhynchophylla. J. Natural Prod. 80, 959–964.
Not in our library10.1021/acs.jnatprod.6b00938
115.
Geny C. Abou Samra A. Retailleau P. Iorga B. I. Nedev H. Awang K. (2017 ). (+)- and (-)-Ecarlottones, Uncommon Chalconoids from Fissistigma latifolium with Pro-Apoptotic Activity. J. Natural Prod. 80, 3179–3185.
Not in our library10.1021/acs.jnatprod.7b00494
116.
Gerlinger C. K. G. Kruger S. Gaich T. (2018 ). Total Synthesis of Parvineostemonine by Structure Pattern Recognition: A Unified Approach to Stemona and Sarpagine Alkaloids. Chem. (Weinheim an der Bergstrasse Germany) 24, 3994–3997.
Not in our library10.1002/chem.201800365
117.
Glaab E. (2016 ). Building a virtual ligand screening pipeline using free software: A survey. Briefings Bioinf. 17, 352–366.
Not in our library10.1093/bib/bbv037
118.
Gobu F.-R. Chen J.-J. Zeng J. Wei W.-J. Wang W.-F. Lin C.-J. (2017 ). Isolation, Structure Elucidition, and Immunosuppressive Activity of Diterpenoids from Ligularia fischeri. J. Natural Prod. 80, 2263–2268.
Not in our library10.1021/acs.jnatprod.7b00198
119.
Gomes N. G. M. Pereira D. M. Valentão P. Andrade P. B. (2018 ). Hybrid MS/NMR methods on the prioritization of natural products: Applications in drug discovery. J. Pharm. Biomed. Anal. 147, 234–249.
Not in our library10.1016/j.jpba.2017.07.035
120.
Grabowski K. Schneider G. (2007 ). Properties and Architecture of Drugs and Natural Products Revisited. Curr. Chem. Biol. 1, 115–127.
Not in our library10.2174/187231307779814066
121.
Grabowski K. Baringhaus K.-H. Schneider G. (2008 ). Scaffold diversity of natural products: inspiration for combinatorial library design. Nat. Prod. Rep. 25, 892–904.
Not in our library10.1039/b715668p
122.
Graves P. R. Kwiek J. J. Fadden P. Ray R. Hardeman K. Coley A. M. (2002 ). Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 62, 1364–1372.
Not in our library10.1124/mol.62.6.1364
123.
Use of Natural Products as Chemical Library for Drug Discovery and Network Pharmacology · 2013
No notice
124.
Guerrero R. O. Guzman A. L. (1998 ). Inhibition of xanthine oxidase by Puerto Rican plant extracts. Puerto Rico Health Sci. J. 17, 359–364.
Not in our library
125.
Gui C. Zhang S. Zhu X. Ding W. Huang H. Gu Y.-C. (2017 ). Antimicrobial Spirotetronate Metabolites from Marine-Derived Micromonospora harpali SCSIO GJ089. J. Natural Prod. 80, 1594–1603.
Not in our library10.1021/acs.jnatprod.7b00176
126.
Gunatilaka A. A. L. (2006 ). Natural products from plant-associated microorganisms: distribution, structural diversity, bioactivity, and implications of their occurrence. J. Natural Prod. 69, 509–526.
Not in our library10.1021/np058128n
127.
Guo Y. Zhang N. Chen C. Huang J. Li X.-N. Liu J. (2017 ). Tricyclic Polyprenylated Acylphloroglucinols from St John’s Wort, Hypericum perforatum. J. Natural Prod. 80, 1493–1504.
Not in our library10.1021/acs.jnatprod.6b01178
128.
Guo X. Shen H. Liu Y. Wang Q. Wang X. Peng C. (2019 ). Enabling Heterologous Synthesis of Lupulones in the Yeast Saccharomyces cerevisiae. Appl. Biochem. Biotechnol. 188, 787–797.
Not in our library10.1007/s12010-019-02957-8
129.
Hann M. M. Leach A. R. Harper G. (2001 ). Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41, 856–864.
Not in our library10.1021/ci000403i
130.
Harvey A. L. Cree I. A. (2010 ). High-throughput screening of natural products for cancer therapy. Planta Med. 76, 1080–1086.
Not in our library10.1055/s-0030-1250162
131.
Harvey A. L. Edrada-Ebel R. Quinn R. J. (2015 ). The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug Discovery 14, 111–129.
Not in our library10.1038/nrd4510
132.
Hatakeyama S. (2018 ). Stereocontrolled Total Synthesis of Biologically Active Natural Products. Yakugaku Zasshi: J. Pharm. Soc. Jpn. 138, 191–209.
Not in our library10.1248/yakushi.17-00187
133.
He Y. Hu Z. Li Q. Huang J. Li X.-N. Zhu H. (2017 ). Bioassay-Guided Isolation of Antibacterial Metabolites from Emericella sp. TJ29. J. Natural Prod. 80, 2399–2405.
Not in our library10.1021/acs.jnatprod.7b00077
134.
Genotypic and Environmental Effects on the Volatile Chemotype of Valeriana jatamansi Jones · 2018
Not checked
135.
Heinamaki J. Pirttimaa M. M. Alakurtti S. Pitkanen H. P. Kanerva H. Hulkko J. (2017 ). Suberin Fatty Acids from Outer Birch Bark: Isolation and Physical Material Characterization. J. Natural Prod. 80, 916–924.
Not in our library10.1021/acs.jnatprod.6b00771
136.
Heinrich M. Barnes J. Prieto-Garcia J. Gibbons S. Williamson E. (2018 ). Fundamentals of Pharmacognosy and Phytotherapy. 3rd Edition (London: Elsevier Health Sciences)9780702070075.
Not in our library
137.
Hendra R. Keller P. A. (2017 ). Phytochemical Studies on Two Australian Anigozanthos Plant Species. J. Natural Prod. 80, 2141–2145.
Not in our library10.1021/acs.jnatprod.7b00063
138.
Henkel T. Brunne R. M. Müller H. Reichel F. (1999 ). Statistical Investigation into the Structural Complementarity of Natural Products and Synthetic Compounds. Angew. Chem. Int. Ed. Engl. 38, 643–647.
Not in our library10.1002/(sici)1521-3773(19990301)38:5<643:aid-anie643>3.0.co;2-g
139.
Henz Ryen A. Backlund A. (2019 ). Charting Angiosperm Chemistry: Evolutionary Perspective on Specialized Metabolites Reflected in Chemical Property Space. J. Nat. Prod. (Gorakhpur) 82, 798–812.
Not in our library10.1021/acs.jnatprod.8b00767
140.
Herraiz T. Guillen H. (2018 ). Monoamine Oxidase-A Inhibition and Associated Antioxidant Activity in Plant Extracts with Potential Antidepressant Actions. BioMed. Res. Int. 2018, 4810394.
Not in our library10.1155/2018/4810394
141.
Hien T. T. T. Quang T. H. Tai B. H. Nhiem N. X. Yen P. H. Yen D. T. H. (2018 ). Iridoid Glycosides and Phenolic Glycosides from Buddleja asiatica with Anti-inflammatory and Cytoprotective Activities. Natural Prod. Commun. 13, 1–4.
Not in our library10.1177/1934578x1801300102
142.
Hong M. J. Kim J. (2017 ). Determination of the Absolute Configuration of Khellactone Esters from Peucedanum japonicum Roots. J. Natural Prod. 80, 1354–1360.
Not in our library10.1021/acs.jnatprod.6b00947
143.
Hong J. (2011 ). Role of natural product diversity in chemical biology. Curr. Opin. Chem. Biol. 15, 350–354.
Not in our library10.1016/j.cbpa.2011.03.004
144.
Horvath D. Lisurek M. Rupp B. Kühne R. Specker E. Kries J. (2014 ). Design of a general-purpose European compound screening library for EU-OPENSCREEN. ChemMedChem 9, 2309–2326.
Not in our library10.1002/cmdc.201402126
145.
Hou J.-Q. Guo C. Zhao J.-J. Dong Y.-Y. Hu X.-L. He Q.-W. (2017 ). Anti-inflammatory Meroterpenoids from Baeckea frutescens. J. Natural Prod. 80, 2204–2214.
Not in our library10.1021/acs.jnatprod.7b00042
146.
Hsiao G. Chi W.-C. Pang K.-L. Chen J.-J. Kuo Y.-H. Wang Y.-K. (2017 ). Hirsutane-Type Sesquiterpenes with Inhibitory Activity of Microglial Nitric Oxide Production from the Red Alga-Derived Fungus Chondrostereum sp. NTOU4196. J. Natural Prod. 80, 1615–1622.
Not in our library10.1021/acs.jnatprod.7b00196
147.
Hu Y. Gupta-Ostermann D. Bajorath J. (2014 ). Exploring Compound Promiscuity Patterns and Multi-Target Activity Spaces. Comput. Struct. Biotechnol. J. 9,e201401003.
Not in our library10.5936/csbj.201401003
148.
Hu Z.-X. Liu M. Wang W.-G. Li X.-N. Hu K. Li X.-R. (2018 ). 7alpha,20-Epoxy-ent-kaurane Diterpenoids from the Aerial Parts of Isodon pharicus. J. Natural Prod. 81, 106–116.
Not in our library10.1021/acs.jnatprod.7b00723
149.
Huang H. Wu D. Tian W.-X. Ma X.-F. Wu X.-D. (2008 ). Antimicrobial effect by extracts of rhizome of Alpinia officinarum Hance may relate to its inhibition of β-ketoacyl-ACP reductase. J. Enzyme Inhib. Med. Chem. 23, 362–368.
Not in our library10.1080/14756360701622099
150.
Huang W.-Y. Wang X.-N. Wang J. Sui Z.-Q. (2018 ). Malvidin and its glycosides from vaccinium ashei improve endothelial function by anti-inflammatory and angiotensin I-converting enzyme inhibitory effects. Natural Prod. Commun. 13, 49–52.
Not in our library10.1177/1934578x1801300115
151.
Huh J. Ha T. K. Q. Kang K. B. Kim K. H. Oh W. K. Kim J. (2017 ). C-Methylated Flavonoid Glycosides from Pentarhizidium orientale Rhizomes and Their Inhibitory Effects on the H1N1 Influenza Virus. J. Natural Prod. 80, 2818–2824.
Not in our library10.1021/acs.jnatprod.7b00677
152.
Ifie I. Marshall L. J. Ho P. Williamson G. (2016 ). Hibiscus sabdariffa (Roselle) Extracts and Wine: Phytochemical Profile, Physicochemical Properties, and Carbohydrase Inhibition. J. Agric. Food Chem. 64, 4921–4931.
Not in our library10.1021/acs.jafc.6b01246
153.
Ikram N. K. B. K. Simonsen H. T. (2017 ). A Review of Biotechnological Artemisinin Production in Plants. Front. Plant Sci. 8, 1966.
Not in our library10.3389/fpls.2017.01966
154.
Imseng N. Schillberg S. Schürch C. Schmid D. Schütte K. Gorr G. (2014 ). ““Suspension Culture of Plant Cells Under Heterotrophic Conditions,” in Industrial scale suspension culture of living cells. Eds. Meyer H.-P. Schmidhalter D. R. (Weinheim, Germany: Wiley Blackwell), 224–258.
Not in our library
155.
Irwin J. A. (2010 ). Extremophiles and their application to veterinary medicine. Environ. Technol. 31, 857–869.
Not in our library10.1080/09593330.2010.484073
156.
Ishibashi M. Ohtsuki T. (2008 ). Studies on search for bioactive natural products targeting TRAIL signaling leading to tumor cell apoptosis. Med. Res. Rev. 28, 688–714.
Not in our library10.1002/med.20123
157.
Issac M. Aknin M. Gauvin-Bialecki A. Voogd N. Ledoux A. Frederich M. (2017 ). Cyclotheonellazoles A-C, Potent Protease Inhibitors from the Marine Sponge Theonella aff. swinhoei. J. Natural Prod. 80, 1110–1116.
Not in our library10.1021/acs.jnatprod.7b00028
158.
Iwasaki A. Shiota I. Sumimoto S. Matsubara T. Sato T. Suenaga K. (2017 ). Kohamamides A, B, and C, Cyclic Depsipeptides from an Okeania sp. Marine Cyanobacterium. J. Natural Prod. 80, 1948–1952.
Not in our library10.1021/acs.jnatprod.7b00256
159.
Jack B. U. Malherbe C. J. Willenburg E. L. Beer D. Huisamen B. Joubert E. (2018 ). Polyphenol-Enriched Fractions of Cyclopia intermedia Selectively Affect Lipogenesis and Lipolysis in 3T3-L1 Adipocytes. Planta Med. 84, 100–110.
Not in our library10.1055/s-0043-119463
160.
Jaeger D. Ndi C. P. Crocoll C. Simpson B. S. Khakimov B. Guzman-Genuino R. M. (2017 ). Isolation and Structural Characterization of Echinocystic Acid Triterpenoid Saponins from the Australian Medicinal and Food Plant Acacia ligulata. J. Natural Prod. 80, 2692–2698.
Not in our library10.1021/acs.jnatprod.7b00437
161.
Jalencas X. Mestres J. (2013 ). On the origins of drug polypharmacology. Medchemcomm 4, 80–87.
Not in our library10.1039/c2md20242e
162.
Jang H.-J. Lee S. Lee S.-J. Lim H.-J. Jung K. Kim Y. H. (2017 ). Anti-inflammatory Activity of Eudesmane-Type Sesquiterpenoids from Salvia plebeia. J. Natural Prod. 80, 2666–2676.
Not in our library10.1021/acs.jnatprod.7b00326
163.
Jang J.-P. Nogawa T. Futamura Y. Shimizu T. Hashizume D. Takahashi S. (2017 ). Octaminomycins A and B, Cyclic Octadepsipeptides Active against Plasmodium falciparum. J. Natural Prod. 80, 134–140.
Not in our library10.1021/acs.jnatprod.6b00758
164.
Jayanetti D. R. Li Y. Bartholomeusz G. A. Bills G. F. Gloer J. B. (2017 ). Benzophenone and Fimetarone Derivatives from the Coprophilous Fungus Delitschia confertaspora. J. Natural Prod. 80, 707–712.
Not in our library10.1021/acs.jnatprod.6b01091
165.
Jian J. Fan J. Yang H. Lan P. Li M. Liu P. (2018 ). Total Synthesis of the Flavonoid Natural Product Houttuynoid A. J. Natural Prod. 81, 371–377.
Not in our library10.1021/acs.jnatprod.7b00791
166.
Jiang B. Zhao W. Li S. Liu H. Yu L. Zhang Y. (2017 ). Cytotoxic Dibohemamines D-F from a Streptomyces Species. J. Natural Prod. 80, 2825–2829.
Not in our library10.1021/acs.jnatprod.7b00136
167.
Jiang H. Zhang G.-J. Liu Y.-F. Wang H.-S. Liang D. (2017 ). Clerodane Diterpenoid Glucosides from the Stems of Tinospora sinensis. J. Natural Prod. 80, 975–982.
Not in our library10.1021/acs.jnatprod.6b00976
168.
Jiang H.-Y. Wang W.-G. Tang J.-W. Liu M. Li X.-R. Hu K. (2017 ). Structurally Diverse Diterpenoids from Isodon scoparius and Their Bioactivity. J. Natural Prod. 80, 2026–2036.
Not in our library10.1021/acs.jnatprod.7b00163
169.
Jiang L. Liu X. Yuan P. Zhang Y. Chen X. (2017 ). Stereoselective Synthesis of (+)-Annuionone A and (-)-Annuionone B. J. Natural Prod. 80, 805–812.
Not in our library10.1021/acs.jnatprod.6b00522
170.
Jin J. B. Cai B. Zhou J.-M. (2017 ). “Salicylic acid,” in Hormone Metabolism and Signaling in Plants (London: Academic Press), 273–289.
Not in our library
171.
Jin Y. Fan J.-T. Gu X.-L. Zhang L.-Y. Han J. Du S.-H. (2017 ). Neuroprotective Activity of Cerebrosides from Typhonium giganteum by Regulating Caspase-3 and Bax/Bcl-2 Signaling Pathways in PC12 Cells. J. Natural Prod. 80, 1734–1741.
Not in our library10.1021/acs.jnatprod.6b00954
172.
Johnson R. E. Ree H. Hartmann M. Lang L. Sawano S. Sarpong R. (2019 ). Total Synthesis of Pentacyclic (-)-Ambiguine P Using Sequential Indole Functionalizations. J. Am. Chem. Soc. 141, 2233–2237.
Not in our library10.1021/jacs.8b13388
173.
Jozwiak A. Ples M. Skorupinska-Tudek K. Kania M. Dydak M. Danikiewicz W. (2013 ). Sugar availability modulates polyisoprenoid and phytosterol profiles in Arabidopsis thaliana hairy root culture. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1831, 438–447.
Not in our library10.1016/j.bbalip.2012.11.006
174.
Kalansuriya P. Quezada M. Esposito B. P. Capon R. J. (2017 ). Talarazines A-E: Noncytotoxic Iron(III) Chelators from an Australian Mud Dauber Wasp-Associated Fungus, Talaromyces sp. (CMB-W045). J. Natural Prod. 80, 609–615.
Not in our library10.1021/acs.jnatprod.6b00889
175.
Kang K. B. Kim H. W. Kim J. W. Oh W. K. Kim J. Sung S. H. (2017 a). Catechin-Bound Ceanothane-Type Triterpenoid Derivatives from the Roots of Zizyphus jujuba. J. Natural Prod. 80, 1048–1054.
Not in our library10.1021/acs.jnatprod.6b01103
176.
Kang K. B. Park E. J. Kim J. Sung S. H. (2017 b). Berchemiosides A-C, 2-Acetoxy-omega-phenylpentaene Fatty Acid Triglycosides from the Unripe Fruits of Berchemia berchemiifolia. J. Natural Prod. 80, 2778–2786.
Not in our library10.1021/acs.jnatprod.7b00602
177.
Kang S.-Y. Heo K. T. Hong Y.-S. (2018 ). Optimization of Artificial Curcumin Biosynthesis in E. coli by Randomized 5′-UTR Sequences To Control the Multienzyme Pathway. ACS Synth. Biol. 7, 2054–2062.
Not in our library10.1021/acssynbio.8b00198
178.
Kant R. Yen C.-H. Lu C.-K. Lin Y.-C. Li J.-H. Chen Y.-M. (2016 ). Identification of 1,2,3,4,6-Penta-O-galloyl-β-d-glucopyranoside as a Glycine N-Methyltransferase Enhancer by High-Throughput Screening of Natural Products Inhibits Hepatocellular Carcinoma. IJMS 17, 669.
Not in our library10.3390/ijms17050669
179.
Karker M. Tommasi N. Smaoui A. Abdelly C. Ksouri R. Braca A. (2016 ). New Sulphated Flavonoids from Tamarix africana and Biological Activities of Its Polar Extract. Planta Med. 82, 1374–1380.
Not in our library10.1055/s-0042-111520
180.
Kauhl U. Andernach L. Opatz T. (2018 ). Total Synthesis of epi-Trichosetin. J. Org. Chem. 83, 15170–15177.
Not in our library10.1021/acs.joc.8b02450
181.
Kayani W. K. Kiani B. H. Dilshad E. Mirza B. (2018 ). Biotechnological approaches for artemisinin production in Artemisia. World J. Microbiol. Biotechnol. 34, 2542.
Not in our library10.1007/s11274-018-2432-9
182.
Khan R. Quradha M. M. Saif A. Q. Ali J. Rauf A. Khan A. (2014 ). Comparative urease enzyme inhibition profile of leaves and stems of Rumex nervosus vahl. Natural Prod. Res. 28, 2355–2357.
Not in our library10.1080/14786419.2014.940346
183.
Khan H. Saeed M. Muhammad N. Gaffar R. Gul F. Raziq N. (2015 ). Lipoxygenase and urease inhibition of the aerial parts of the Polygonatum verticillatum. Toxicol. Ind. Health 31, 758–763.
Not in our library10.1177/0748233713483197
184.
Khan T. Abbasi B. H. Khan M. A. Shinwari Z. K. (2016 ). Differential Effects of Thidiazuron on Production of Anticancer Phenolic Compounds in Callus Cultures of Fagonia indica. Appl. Biochem. Biotechnol. 179, 46–58.
Not in our library10.1007/s12010-016-1978-y
185.
Khanpour-Ardestani N. Sharifi M. Behmanesh M. (2015 ). Establishment of callus and cell suspension culture of Scrophularia striata Boiss. an in vitro approach for acteoside production. Cytotechnology 67, 475–485.
Not in our library10.1007/s10616-014-9705-4
186.
Kil Y.-S. Kim S. M. Kang U. Chung H. Y. Seo E. K. (2017 ). Peroxynitrite-Scavenging Glycosides from the Stem Bark of Catalpa ovata. J. Natural Prod. 80, 2240–2251.
Not in our library10.1021/acs.jnatprod.7b00139
187.
Kim S.-I. Yang E.-J. Park S.-H. Kim C.-K. Song K.-S. (2014 ). A β-secretase (BACE1)-inhibiting C-methylrotenoid induced by yeast elicitation in Abronia nana suspension cultures. Appl. Biochem. Biotechnol. 172, 3529–3537.
Not in our library10.1007/s12010-014-0762-0
188.
Kim C.-K. Riswanto R. Won T. H. Kim H. Elya B. Sim C. J. (2017 ). Manzamine Alkaloids from an Acanthostrongylophora sp. Sponge. J. Natural Prod. 80, 1575–1583.
Not in our library10.1021/acs.jnatprod.7b00121
189.
Kim K. Kim J.-J. Jung Y. Noh J.-Y. Syed A. S. Kim C. Y. (2017 ). Cyclocurcumin, an Antivasoconstrictive Constituent of Curcuma longa (Turmeric). J. Natural Prod. 80, 196–200.
Not in our library10.1021/acs.jnatprod.6b00331
190.
Kim C. S. Bae M. Oh J. Subedi L. Suh W. S. Choi S. Z. (2017 a). Anti-Neurodegenerative Biflavonoid Glycosides from Impatiens balsamina. J. Natural Prod. 80, 471–478.
Not in our library10.1021/acs.jnatprod.6b00981
191.
Kim C. S. Subedi L. Oh J. Kim S. Y. Choi S. U. Lee K. R. (2017 b). Bioactive Triterpenoids from the Twigs of Chaenomeles sinensis. J. Natural Prod. 80, 1134–1140.
Not in our library10.1021/acs.jnatprod.7b00111
192.
Kim G. Kim M. J. Chung G. Lee H.-Y. Han S. (2018 ). (+)-Dimericbiscognienyne A: Total Synthesis and Mechanistic Investigations of the Key Heterodimerization. Org. Lett. 20, 6886–6890.
Not in our library10.1021/acs.orglett.8b03025
193.
Kimura S. Saito N. (2018 ). Construction of the Pentacyclic Core and Formal Total Synthesis of (rac)-Renieramycin T. ChemistryOpen 7, 764–771.
Not in our library10.1002/open.201800112
194.
Kinnel R. B. Esquenazi E. Leao T. Moss N. Mevers E. Pereira A. R. (2017 ). A Maldiisotopic Approach to Discover Natural Products: Cryptomaldamide, a Hybrid Tripeptide from the Marine Cyanobacterium Moorea producens. J. Natural Prod. 80, 1514–1521.
Not in our library10.1021/acs.jnatprod.7b00019
195.
Kirby J. Keasling J. D. (2009 ). Biosynthesis of plant isoprenoids: perspectives for microbial engineering. Annu. Rev. Plant Biol. 60, 335–355.
Not in our library10.1146/annurev.arplant.043008.091955
196.
Klein-Junior L. C. Cretton S. Allard P.-M. Genta-Jouve G. Passos C. S. Salton J. (2017 ). Targeted Isolation of Monoterpene Indole Alkaloids from Palicourea sessilis. J. Natural Prod. 80, 3032–3037.
Not in our library10.1021/acs.jnatprod.7b00681
197.
Kravina A. G. Carreira E. M. (2018 ). Total Synthesis of Epicolactone. Angew. Che. (Int. Ed. English) 57, 13159–13162.
Not in our library10.1002/anie.201807709
198.
Kruakaew S. Seeka C. Lhinhatrakool T. Thongnest S. Yahuafai J. Piyaviriyakul S. (2017 ). Cytotoxic Cardiac Glycoside Constituents of Vallaris glabra Leaves. J. Natural Prod. 80, 2987–2996.
Not in our library10.1021/acs.jnatprod.7b00554
199.
Krueger B. A. Dietrich A. Baringhaus K.-H. Schneider G. (2009 ). Scaffold-hopping potential of fragment-based de novo design: the chances and limits of variation. Comb. Chem. High Throughput Screen. 12, 383–396.
Not in our library10.2174/138620709788167971
200.
Kruger A. Schafers C. Schroder C. Antranikian G. (2018 ). Towards a sustainable biobased industry - Highlighting the impact of extremophiles. New Biotechnol. 40, 144–153.
Not in our library10.1016/j.nbt.2017.05.002
201.
Kubota T. Nakamura K. Kurimoto S.-I. Sakai K. Fromont J. Gonoi T. (2017 ). Zamamidine D, a Manzamine Alkaloid from an Okinawan Amphimedon sp. Marine Sponge. J. Natural Prod. 80, 1196–1199.
Not in our library10.1021/acs.jnatprod.6b01110
202.
Kufareva I. Ilatovskiy A. V. Abagyan R. (2012 ). Pocketome: an encyclopedia of small-molecule binding sites in 4D. Nucleic Acids Res. 40, D535–D540.
Not in our library10.1093/nar/gkr825
203.
Kuo P.-C. Hung H.-Y. Nian C.-W. Hwang T.-L. Cheng J.-C. Kuo D.-H. (2017 ). Chemical Constituents and Anti-inflammatory Principles from the Fruits of Forsythia suspensa. J. Natural Prod. 80, 1055–1064.
Not in our library10.1021/acs.jnatprod.6b01141
204.
Kuo L.-M. Y. Tseng P.-Y. Lin Y.-C. Liaw C.-C. Zhang L.-J. Tsai K.-C. (2018 ). New Hirsutinolide-Type Sesquiterpenoids from Vernonia cinerea Inhibit Nitric Oxide Production in LPS-Stimulated RAW264.7 Cells. Planta Med. 84, 1348–1354.
Not in our library10.1055/a-0647-1901
205.
Kurasawa K. Kwon E. Kuwahara S. Enomoto M. (2018 ). Bioinspired Total Synthesis of Delitschiapyrone A. Org. Lett. 20, 4645–4648.
Not in our library10.1021/acs.orglett.8b01932
206.
Kusakabe K. Honmura Y. Uesugi S. Tonouchi A. Maeda H. Kimura K.-I. (2017 ). Neomacrophorin X, a 4.4.3Propellane-Type Meroterpenoid from Trichoderma sp. 1212-03. J. Natural Prod. 80, 1484–1492.
Not in our library10.1021/acs.jnatprod.6b01177
207.
Kuttruff C. A. Eastgate M. D. Baran P. S. (2014 ). Natural product synthesis in the age of scalability. Nat. Prod. Rep. 31, 419–432.
Not in our library10.1039/c3np70090a
208.
Kwon I.-S. Kwak J. H. Pyo S. Lee H.-W. Kim A. Schmitz F. J. (2017 ). Oscarellin, an Anthranilic Acid Derivative from a Philippine Sponge, Oscarella stillans, as an Inhibitor of Inflammatory Cytokines in Macrophages. J. Natural Prod. 80, 149–155.
Not in our library10.1021/acs.jnatprod.6b00787
209.
Lajter I. Pan S.-P. Nikles S. Ortmann S. Vasas A. Csupor-Löffler B. (2015 ). Inhibition of COX-2 and NF-κB1 Gene Expression, NO Production, 5-LOX, and COX-1 and COX-2 Enzymes by Extracts and Constituents of Onopordum acanthium. Planta Med. 81, 1270–1276.
Not in our library10.1055/s-0035-1546242
210.
Langer T. Hoffmann R. Bryant S. Lesur B. (2009 ). Hit finding: Towards ‘smarter’ approaches. Curr. Opin. Pharmacol. 9, 589–593.
Not in our library10.1016/j.coph.2009.06.001
211.
Larsson J. Gottfries J. Bohlin L. Backlund A. (2005 ). Expanding the ChemGPS chemical space with natural products. J. Natural Prod. 68, 985–991.
Not in our library10.1021/np049655u
212.
Larsson J. Gottfries J. Muresan S. Backlund A. (2007 ). ChemGPS-NP: Tuned for navigation in biologically relevant chemical space. J. Natural Prod. 70, 789–794.
Not in our library10.1021/np070002y
213.
Lautié E. Quintero R. Fliniaux M.-A. Villarreal M.-L. (2008 ). Selection methodology with scoring system: Application to Mexican plants producing podophyllotoxin related lignans. J. Ethnopharmacol. 120, 402–412.
Not in our library10.1016/j.jep.2008.09.014
214.
Lautié E. Fliniaux M.-A. Villarreal M. L. (2010 ). Updated biotechnological approaches developed for 2,7′-cyclolignan production. Biotechnol. Appl. Biochem. 55, 139–153.
Not in our library10.1042/ba20090253
215.
Ledesma-Amaro R. Jiménez A. Revuelta J. L. (2018 ). Pathway Grafting for Polyunsaturated Fatty Acids Production in Ashbya gossypii through Golden Gate Rapid Assembly. ACS Synth. Biol. 7, 2340–2347.
Not in our library10.1021/acssynbio.8b00287
216.
Ledoux A. St-Gelais A. Cieckiewicz E. Jansen O. Bordignon A. Illien B. (2017 ). Antimalarial Activities of Alkyl Cyclohexenone Derivatives Isolated from the Leaves of Poupartia borbonica. J. Natural Prod. 80, 1750–1757.
Not in our library10.1021/acs.jnatprod.6b01019
217.
Lee M. L. Schneider G. (2001 ). Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. J. Comb. Chem. 3, 284–289.
Not in our library10.1021/cc000097l
218.
Lee W. Lee D. Lee Y. Lee T. Song K.-S. Yang E.-J. (2018 ). Isolation, Synthesis, and Antisepsis Effects of a C-Methylcoumarinochromone Isolated from Abronia nana Cell Culture. J. Natural Prod. 81, 1173–1182.
Not in our library10.1021/acs.jnatprod.7b00826
219.
Leman-Loubiere C. Le Goff G. Retailleau P. Debitus C. Ouazzani J. (2017 ). Sporothriolide-Related Compounds from the Fungus Hypoxylon monticulosum CLL-205 Isolated from a Sphaerocladina Sponge from the Tahiti Coast. J. Natural Prod. 80, 2850–2854.
Not in our library10.1021/acs.jnatprod.7b00714
220.
Leo M. Peruzzi L. Granchi C. Tuccinardi T. Minutolo F. Tommasi N. (2017 ). Constituents of Polygala flavescens ssp. flavescens and Their Activity as Inhibitors of Human Lactate Dehydrogenase. J. Natural Prod. 80, 2077–2087.
Not in our library10.1021/acs.jnatprod.7b00295
221.
Li D.-H. Li J.-Y. Xue C.-M. Han T. Sai C.-M. Wang K.-B. (2017 ). Antiproliferative Dimeric Aporphinoid Alkaloids from the Roots of Thalictrum cultratum. J. Natural Prod. 80, 2893–2904.
Not in our library10.1021/acs.jnatprod.7b00387
222.
Li H.-L. Li X.-M. Li X. Wang C.-Y. Liu H. Kassack M. U. (2017 ). Antioxidant Hydroanthraquinones from the Marine Algal-Derived Endophytic Fungus Talaromyces islandicus EN-501. J. Natural Prod. 80, 162–168.
Not in our library10.1021/acs.jnatprod.6b00797
223.
Li K. Ji S. Song W. Kuang Y. Lin Y. Tang S. (2017 ). Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra. J. Natural Prod. 80, 334–346.
Not in our library10.1021/acs.jnatprod.6b00783
224.
Li Q. Deng A.-J. Li L. Wu L.-Q. Ji M. Zhang H.-J. (2017 ). Azacyclo-indoles and Phenolics from the Flowers of Juglans regia. J. Natural Prod. 80, 2189–2198.
Not in our library10.1021/acs.jnatprod.6b00887
225.
Li Y. Yue Q. Jayanetti D. R. Swenson D. C. Bartholomeusz G. A. An Z. (2017 ). Anti-Cryptococcus Phenalenones and Cyclic Tetrapeptides from Auxarthron pseudauxarthron. J. Natural Prod. 80, 2101–2109.
Not in our library10.1021/acs.jnatprod.7b00341
226.
Li J. Gu B.-B. Sun F. Xu J.-R. Jiao W.-H. Yu H.-B. (2017 a). Sesquiterpene Quinones/Hydroquinones from the Marine Sponge Spongia pertusa Esper. J. Natural Prod. 80, 1436–1445.
Not in our library10.1021/acs.jnatprod.6b01105
227.
Li J. Li N. Li X. Chen G. Wang C. Lin B. (2017 b). Characteristic alpha-Acid Derivatives from Humulus lupulus with Antineuroinflammatory Activities. J. Natural Prod. 80, 3081–3092.
Not in our library10.1021/acs.jnatprod.6b00921
228.
Li J. Seupel R. Bruhn T. Feineis D. Kaiser M. Brun R. (2017 c). Jozilebomines A and B, Naphthylisoquinoline Dimers from the Congolese Liana Ancistrocladus ileboensis, with Antiausterity Activities against the PANC-1 Human Pancreatic Cancer Cell Line. J. Natural Prod. 80, 2807–2817.
Not in our library10.1021/acs.jnatprod.7b00650
229.
Li J. Seupel R. Feineis D. Mudogo V. Kaiser M. Brun R. (2017 d). Dioncophyllines C2, D2, and F and Related Naphthylisoquinoline Alkaloids from the Congolese Liana Ancistrocladus ileboensis with Potent Activities against Plasmodium falciparum and against Multiple Myeloma and Leukemia Cell Lines. J. Natural Prod. 80, 443–458.
Not in our library10.1021/acs.jnatprod.6b00967
230.
Li W. Huang C. Liu Q. Koike K. (2017 e). Bistinospinosides A and B, Dimeric Clerodane Diterpene Glycosides from Tinospora sagittata. J. Natural Prod. 80, 2478–2483.
Not in our library10.1021/acs.jnatprod.7b00324
231.
Li W. Lee C. Bang S. H. Ma J. Y. Kim S. Koh Y.-S. (2017 f). Isochromans and Related Constituents from the Endophytic Fungus Annulohypoxylon truncatum of Zizania caduciflora and Their Anti-Inflammatory Effects. J. Natural Prod. 80, 205–209.
Not in our library10.1021/acs.jnatprod.6b00698
232.
Li L. Chen Z. Zhang X. Jia Y. (2018 ). Divergent Strategy in Natural Product Total Synthesis. Chem. Rev. 118, 3752–3832.
Not in our library10.1021/acs.chemrev.7b00653
233.
Li S. Niu H. Qiao Y. Zhu R. Sun Y. Ren Z. (2018 ). Terpenoids isolated from Chinese liverworts Lepidozia reptans and their anti-inflammatory activity. Bioorg. Med. Chem. 26, 2392–2400.
Not in our library10.1016/j.bmc.2018.03.040
234.
Liangsakul P. Kuhakarn C. Hongthong S. Jariyawat S. Suksen K. Akkarawongsapat R. (2018 ). Anti-HIV 1 Activity of Xanthones from the Bark of Mammea harmandii. Natural Prod. Commun. 13, 53–56.
Not in our library10.1177/1934578x1801300116
235.
Lima R. D. C. L. Gramsbergen S. M. van Staden J. Jager A. K. Kongstad K. T. Staerk D. (2017 ). Advancing HPLC-PDA-HRMS-SPE-NMR Analysis of Coumarins in Coleonema album by Use of Orthogonal Reversed-Phase C18 and Pentafluorophenyl Separations. J. Natural Prod. 80, 1020–1027.
Not in our library10.1021/acs.jnatprod.6b01020
236.
Lin Z. Xu X. Zhao S. Yang X. Guo J. Zhang Q. (2018 ). Total synthesis and antimicrobial evaluation of natural albomycins against clinical pathogens. Nat. Commun. 9, 3445.
Not in our library10.1038/s41467-018-05821-1
237.
Lipinski C. A. Lombardo F. Dominy B. W. Feeney P. J. (2001 ). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3–26.
Not in our library10.1016/s0169-409x(00)00129-0
238.
Lipinski C. A. (2003 ). Chris Lipinski discusses life and chemistry after the Rule of Five. Drug Discovery Today 8, 12–16.
Not in our library10.1016/s1359-6446(02)02556-4
239.
Litaudon M. Bousserouel H. Awang K. Nosjean O. Martin M.-T. Dau M. E. T. H. (2009 a). A Dimeric sesquiterpenoid from a Malaysian Meiogyne as a new inhibitor of Bcl-xL/BakBH3 domain peptide interaction. J. Natural Prod. 72, 480–483.
Not in our library10.1021/np8006292
240.
Litaudon M. Jolly C. Le Callonec C. Cuong D. D. Retailleau P. Nosjean O. (2009 b). Cytotoxic pentacyclic triterpenoids from Combretum sundaicum and Lantana camara as inhibitors of Bcl-xL/BakBH3 domain peptide interaction. J. Natural Prod. 72, 1314–1320.
Not in our library10.1021/np900192r
241.
Liu Y.-W. Shi D.-H. Chen A.-J. Zhu Q. Xu J.-T. Zhang X.-X. (2014 ). Acetylcholinesterase inhibition effects of marine fungi. Pharm. Biol. 52, 539–543.
Not in our library10.3109/13880209.2013.850516
242.
Liu F. Yuan T. Liu W. Ma H. Seeram N. P. Li Y. (2017 ). Phloroglucinol Derivatives with Protein Tyrosine Phosphatase 1B Inhibitory Activities from Eugenia jambolana Seeds. J. Natural Prod. 80, 544–550.
Not in our library10.1021/acs.jnatprod.6b01073
243.
Liu H.-B. Lauro G. O’Connor R. D. Lohith K. Kelly M. Colin P. (2017 ). Tulongicin, an Antibacterial Tri-Indole Alkaloid from a Deep-Water Topsentia sp. Sponge. J. Natural Prod. 80, 2556–2560.
Not in our library10.1021/acs.jnatprod.7b00452
244.
Liu L.-L. Ha T. K. Q. Ha W. Oh W. K. Yang J.-L. Shi Y.-P. (2017 ). Sesquiterpenoids with Various Carbocyclic Skeletons from the Flowers of Chrysanthemum indicum. J. Natural Prod. 80, 298–307.
Not in our library10.1021/acs.jnatprod.6b00694
245.
Liu R. Heiss E. H. Schachner D. Jiang B. Liu W. Breuss J. M. (2017 ). Xanthohumol Blocks Proliferation and Migration of Vascular Smooth Muscle Cells in Vitro and Reduces Neointima Formation in Vivo. J. Natural Prod. 80, 2146–2150.
Not in our library10.1021/acs.jnatprod.7b00268
246.
Liu Y. Li Y. Liu Z. Li L. Qu J. Ma S. (2017 a). Sesquiterpenes from the Endophyte Glomerella cingulata. J. Natural Prod. 80, 2609–2614.
Not in our library10.1021/acs.jnatprod.7b00054
247.
Liu Y. Yu H.-Y. Wang Y.-M. Tian T. Wu W.-M. Zhou M. (2017 b). Neuroprotective Lignans from the Fruits of Schisandra bicolor var. tuberculata. J. Natural Prod. 80, 1117–1124.
Not in our library10.1021/acs.jnatprod.7b00035
248.
Liu W.-C. Inwood S. Gong T. Sharma A. Yu L.-Y. Zhu P. (2019 ). Fed-batch high-cell-density fermentation strategies for Pichia pastoris growth and production. Crit. Rev. Biotechnol. 39, 258–271.
Not in our library10.1080/07388551.2018.1554620
249.
Liu X. Liu J. Wu J. Huang G. Liang R. Chung L. W. (2019 ). Asymmetric Total Synthesis of Cerorubenic Acid-III. J. Am. Chem. Soc. 141, 2872–2877.
Not in our library10.1021/jacs.8b12647
250.
Pseudomonas putida—a versatile host for the production of natural products · 2015
No notice
251.
Lu Y. Stegemann S. Agrawal S. Karcher D. Ruf S. Bock R. (2017 ). Horizontal Transfer of a Synthetic Metabolic Pathway between Plant Species. Curr. Biol. 27, 3034–3041.e3.
Not in our library10.1016/j.cub.2017.08.044
252.
Luo J.-G. Xu Y.-M. Sandberg D. C. Arnold A. E. Gunatilaka A. A. L. (2017 ). Montagnuphilones A-G, Azaphilones from Montagnulaceae sp. DM0194, a Fungal Endophyte of Submerged Roots of Persicaria amphibia. J. Natural Prod. 80, 76–81.
Not in our library10.1021/acs.jnatprod.6b00714
253.
Luo P. Xia W. Morris-Natschke S. L. Lee K.-H. Zhao Y. Gu Q. (2017 ). Vitepyrroloids A-D, 2-Cyanopyrrole-Containing Labdane Diterpenoid Alkaloids from the Leaves of Vitex trifolia. J. Natural Prod. 80, 1679–1683.
Not in our library10.1021/acs.jnatprod.6b01195
254.
Luo Q. Wei X.-Y. Yang J. Luo J.-F. Liang R. Tu Z.-C. (2017 ). Spiro Meroterpenoids from Ganoderma applanatum. J. Natural Prod. 80, 61–70.
Not in our library10.1021/acs.jnatprod.6b00431
255.
Ma C. T. Eom T. Cho E. Wu B. Kim T. R. Oh K. B. (2017 ). Aquilanols A and B, Macrocyclic Humulene-Type Sesquiterpenoids from the Agarwood of Aquilaria malaccensis. J. Natural Prod. 80, 3043–3048.
Not in our library10.1021/acs.jnatprod.7b00462
256.
Ma X. Liu J. Yang L. Zhang B. Dong Y. Zhao Q. (2018 ). Cynomorium songaricum prevents bone resorption in ovariectomized rats through RANKL/RANK/TRAF6 mediated suppression of PI3K/AKT and NF-κB pathways. Life Sci. 209, 140–148.
Not in our library10.1016/j.lfs.2018.08.008
257.
Ma L. Tang L. Yi Q. (2019 ). Salvianolic Acids: Potential Source of Natural Drugs for the Treatment of Fibrosis Disease and Cancer. Front. Pharmacol. 10, 97.
Not in our library10.3389/fphar.2019.00097
258.
Macabeo A. P. G. Letada A. G. Budde S. Faderl C. Dahse H.-M. Franzblau S. G. (2017 ). Antitubercular and Cytotoxic Chlorinated seco-Cyclohexenes from Uvaria alba. J. Natural Prod. 80, 3319–3323.
Not in our library10.1021/acs.jnatprod.7b00679
259.
Macarron R. Banks M. N. Bojanic D. Burns D. J. Cirovic D. A. Garyantes T. (2011 ). Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discovery 10, 188–195.
Not in our library10.1038/nrd3368
260.
Malik S. Cusidó R. M. Mirjalili M. H. Moyano E. Palazón J. Bonfill M. (2011 ). Production of the anticancer drug taxol in Taxus baccata suspension cultures: A review. Process Biochem. 46, 23–34.
Not in our library10.1016/j.procbio.2010.09.004
261.
Man Y. Fu S. Chen J. Liu B. (2018 ). Total synthesis and structural revision of an isopanepoxydone analog isolated from Lentinus strigellus. Org. Biomolec. Chem. 16, 5043–5049.
Not in our library10.1039/c8ob01168k
262.
Mancuso S. (2018 ). The revolutionary genius of plants: A new understanding of plant intelligence and behavior (New York NY: Atria Books an imprint of Simon & Schuster Inc.).
Not in our library
263.
Markovic M. Koos P. Carny T. Sokoliova S. Bohacikova N. Moncol J. (2017 ). Total Synthesis, Configuration Assignment, and Cytotoxic Activity Evaluation of Protulactone A. J. Natural Prod. 80, 1631–1638.
Not in our library10.1021/acs.jnatprod.7b00212
264.
Martin H. J. Kampatsikas I. Oost R. Pretzler M. Al-Sayed E. Roller A. (2018 ). Total Synthesis, Stereochemical Assignment, and Divergent Enantioselective Enzymatic Recognition of Larreatricin. Chem. (Weinheim an der Bergstrasse Germany) 24, 15756–15760.
Not in our library10.1002/chem.201803785
265.
Masi M. Meyer S. Clement S. Pescitelli G. Cimmino A. Cristofaro M. (2017 ). Chloromonilinic Acids C and D, Phytotoxic Tetrasubstituted 3-Chromanonacrylic Acids Isolated from Cochliobolus australiensis with Potential Herbicidal Activity against Buffelgrass (Cenchrus ciliaris). J. Natural Prod. 80, 2771–2777.
Not in our library10.1021/acs.jnatprod.7b00583
266.
Mathur A. Mathur A. K. Pal M. Uniyal G. C. (1999 ). Comparison of qualitative and quantitative in vitro ginsenoside production in callus cultures of three Panax species. Planta Med. 65, 484–486.
Not in our library10.1055/s-2006-960823
267.
Mayr L. M. Bojanic D. (2009 ). Novel trends in high-throughput screening. Curr. Opin. Pharmacol. 9, 580–588.
Not in our library10.1016/j.coph.2009.08.004
268.
Mazzio E. Badisa R. Mack N. Deiab S. Soliman K. F. A. (2014 ). High Throughput Screening of Natural Products for Anti-mitotic Effects in MDA-MB-231 Human Breast Carcinoma Cells. Phytother. Res. 28, 856–867.
Not in our library10.1002/ptr.5065
269.
McMullin D. R. Green B. D. Prince N. C. Tanney J. B. Miller J. D. (2017 ). Natural Products of Picea Endophytes from the Acadian Forest. J. Natural Prod. 80, 1475–1483.
Not in our library10.1021/acs.jnatprod.6b01157
270.
Melchor-Martinez E. M. Silva-Mares D. A. Torres-Lopez E. Waksman-Minsky N. Pauli G. F. Chen S.-N. (2017 ). Stereochemistry of a Second Riolozane and Other Diterpenoids from Jatropha dioica. J. Natural Prod. 80, 2252–2262.
Not in our library10.1021/acs.jnatprod.7b00193
271.
Mestres J. Gregori-Puigjané E. Valverde S. Solé R. V. (2008 ). Data completeness—the Achilles heel of drug-target networks. Nat. Biotechnol. 26, 983–984.
Not in our library10.1038/nbt0908-983
272.
Mieri M. Monteleone G. Ismajili I. Kaiser M. Hamburger M. (2017 ). Antiprotozoal Activity-Based Profiling of a Dichloromethane Extract from Anthemis nobilis Flowers. J. Natural Prod. 80, 459–470.
Not in our library10.1021/acs.jnatprod.6b00980
273.
Mo D.-J. Li J. Li M.-Y. (2018 ). A New 28-Nor-oleanane Triterpene from Excoecaria agallocha. Natural Prod. Commun. 13, 17–20.
Not in our library10.1177/1934578x1801300107
274.
Mokashe N. Chaudhari B. Patil U. (2018 ). Operative utility of salt-stable proteases of halophilic and halotolerant bacteria in the biotechnology sector. Int. J. Biol. Macromol. 117, 493–522.
Not in our library10.1016/j.ijbiomac.2018.05.217
275.
Moore B. D. Andrew R. L. Külheim C. Foley W. J. (2014 ). Explaining intraspecific diversity in plant secondary metabolites in an ecological context. New Phytol. 201, 733–750.
Not in our library10.1111/nph.12526
276.
Mortenson P. N. Erlanson D. A. Esch I. J. P. de Jahnke W. Johnson C. N. (2018 ). Fragment-to-Lead Medicinal Chemistry Publications in 2017. J. Med. Chem. 62, 3857–3872.
Not in our library10.1021/acs.jmedchem.8b01472
277.
Moscatiello R. Baldan B. Navazio L. (2013 ). Plant cell suspension cultures. Methods Mol. Biol. (Clifton N.J.) 953, 77–93.
Not in our library10.1007/978-1-62703-152-3_5
278.
Moses T. Mehrshahi P. Smith A. G. Goossens A. (2017 ). Synthetic biology approaches for the production of plant metabolites in unicellular organisms. J. Exp. Bot. 68, 4057–4074.
Not in our library10.1093/jxb/erx119
279.
Mountessou B. Y. G. Tchamgoue J. Paul Dzoyem J. Tchuenguem R. T. Surup F. Choudhary M. I. (2018 ). Two xanthones and two rotameric (3⟶8) biflavonoids from the Cameroonian medicinal plant Allanblackia floribunda Oliv. (Guttiferae). Tetrahedron Lett. 59, 4545–4550.
Not in our library10.1016/j.tetlet.2018.11.035
280.
Muharini R. Diaz A. Ebrahim W. Mandi A. Kurtan T. Rehberg N. (2017 ). Antibacterial and Cytotoxic Phenolic Metabolites from the Fruits of Amorpha fruticosa. J. Natural Prod. 80, 169–180.
Not in our library10.1021/acs.jnatprod.6b00809
281.
Mustafa N. R. Winter W. van Iren F. Verpoorte R. (2011 ). Initiation, growth and cryopreservation of plant cell suspension cultures. Nat. Protoc. 6, 715–742.
Not in our library10.1038/nprot.2010.144
282.
Nadri M. H. Salim Y. Basar N. Yahya A. Zulkifli R. M. (2014 ). Antioxidant activities and tyrosinase inhibition effects of Phaleria macrocarpa extracts. Afr. J. Tradit. Complement. Altern. Medicines: AJTCAM 11, 107–111.
Not in our library10.4314/ajtcam.v11i3.16
283.
Naman C. B. Almaliti J. Armstrong L. Caro-Diaz E. J. Pierce M. L. Glukhov E. (2017 ). Discovery and Synthesis of Caracolamide A, an Ion Channel Modulating Dichlorovinylidene Containing Phenethylamide from a Panamanian Marine Cyanobacterium cf. Symploca Species. J. Natural Prod. 80, 2328–2334.
Not in our library10.1021/acs.jnatprod.7b00367
284.
Nduka S. O. Okonta M. J. Ajaghaku D. L. Ukwe C. V. (2017 ). In vitro and in vivo cytochrome P450 3A enzyme inhibition by Aframomum melegueta and Denniettia tripetala extracts. Asian Pacific J. Trop. Med. 10, 576–581.
Not in our library10.1016/j.apjtm.2017.06.006
285.
Newman D. J. Cragg G. M. (2007 ). Natural products as sources of new drugs over the last 25 years. J. Natural Prod. 70, 461–477.
Not in our library10.1021/np068054v
286.
Newman D. J. Cragg G. M. (2012 ). Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Natural Prod. 75, 311–335.
Not in our library10.1021/np200906s
287.
Newman D. J. Cragg G. M. (2015 ). Endophytic and epiphytic microbes as “sources” of bioactive agents. Front. Chem. 3, 34.
Not in our library10.3389/fchem.2015.00034
288.
Newman D. J. Cragg G. M. (2016 ). Natural Products as Sources of New Drugs from 1981 to 2014. J. Natural Prod. 79, 629–661.
Not in our library10.1021/acs.jnatprod.5b01055
289.
Newman D. J. Cragg G. M. Snader K. M. (2003 ). Natural products as sources of new drugs over the period 1981-2002. J. Natural Prod. 66, 1022–1037.
Not in our library10.1021/np030096l
290.
Nguyen D. M. T. Do L. M. T. Nguyen V. T. Chavasiri W. Mortier J. Nguyen P. P. K. (2017 ). Phenolic Compounds from the Lichen Lobaria orientalis. J. Natural Prod. 80, 261–268.
Not in our library10.1021/acs.jnatprod.6b00465
291.
Nguyen M. T. T. Le T. H. Nguyen H. X. Dang P. H. Do T. N. V. Abe M. (2017 ). Artocarmins G-M, Prenylated 4-Chromenones from the Stems of Artocarpus rigida and Their Tyrosinase Inhibitory Activities. J. Natural Prod. 80, 3172–3178.
Not in our library10.1021/acs.jnatprod.7b00453
292.
Nguyen N. T. Dang P. H. Vu N. X. T. Le T. H. Nguyen M. T. T. (2017 a). Quinoliniumolate and 2H-1,2,3-Triazole Derivatives from the Stems of Paramignya trimera and Their alpha-Glucosidase Inhibitory Activities: In Vitro and in Silico Studies. J. Natural Prod. 80, 2151–2155.
Not in our library10.1021/acs.jnatprod.7b00289
293.
Nguyen N. T. Nguyen M. T. T. Nguyen H. X. Dang P. H. Dibwe D. F. Esumi H. (2017 b). Constituents of the Rhizomes of Boesenbergia pandurata and Their Antiausterity Activities against the PANC-1 Human Pancreatic Cancer Line. J. Natural Prod. 80, 141–148.
Not in our library10.1021/acs.jnatprod.6b00784
294.
Ni G. Li J.-Y. Mai Z.-P. Yu D.-Q. (2018 ). Belamcandanes A and B, two unprecedented tricyclic-iridal triterpenoids from Belamcanda chinensis. Tetrahedron Lett. 59, 151–155.
Not in our library10.1016/j.tetlet.2017.12.013
295.
Nicacio K. J. Ioca L. P. Froes A. M. Leomil L. Appolinario L. R. Thompson C. C. (2017 ). Cultures of the Marine Bacterium Pseudovibrio denitrificans Ab134 Produce Bromotyrosine-Derived Alkaloids Previously Only Isolated from Marine Sponges. J. Natural Prod. 80, 235–240.
Not in our library10.1021/acs.jnatprod.6b00838
296.
Nicolaou K. C. Li R. Lu Z. Pitsinos E. N. Alemany L. B. (2018 a). Total Synthesis and Full Structural Assignment of Namenamicin. J. Am. Chem. Soc. 140, 8091–8095.
Not in our library10.1021/jacs.8b04592
297.
Nicolaou K. C. Li R. Lu Z. Pitsinos E. N. Alemany L. B. Aujay M. (2018 b). Streamlined Total Synthesis of Shishijimicin A and Its Application to the Design, Synthesis, and Biological Evaluation of Analogues thereof and Practical Syntheses of PhthNSSMe and Related Sulfenylating Reagents. J. Am. Chem. Soc. 140, 12120–12136.
Not in our library10.1021/jacs.8b06955
298.
Nikel P. I. Martínez-García E. Lorenzo V. (2014 ). Biotechnological domestication of pseudomonads using synthetic biology. Nat. Rev. Microbiol. 12, 368–379.
Not in our library10.1038/nrmicro3253
299.
Ninomiya M. Ando Y. Kudo F. Ohmori K. Suzuki K. (2019 ). First Total Synthesis of Actinorhodin. Angew. Che. (Int. Ed. English). 58, 4264–4270.
Not in our library10.1002/anie.201814172
300.
Nistanaki S. K. Boralsky L. A. Pan R. D. Nelson H. M. (2019 ). A Concise Total Synthesis of (+/-)-Vibralactone. Angew. Che. (Int. Ed. English) 58, 1724–1726.
Not in our library10.1002/anie.201812711
301.
Niu B. Ke C.-Q. Li B.-H. Li Y. Yi Y. Luo Y. (2017 ). Cucurbitane Glucosides from the Crude Extract of Siraitia grosvenorii with Moderate Effects on PGC-1alpha Promoter Activity. J. Natural Prod. 80, 1428–1435.
Not in our library10.1021/acs.jnatprod.6b01086
302.
Niu S. Fan Z. Tang X. Liu Q. Shao Z. Liu G. (2018 ). Cyclopiane-type diterpenes from the deep-sea-derived fungus Penicillium commune MCCC 3A00940. Tetrahedron Lett. 59, 375–378.
Not in our library10.1016/j.tetlet.2017.12.045
303.
Nolsoe J. M. J. Antonsen S. Gorbitz C. H. Hansen T. V. Nesman J. I. Rohr A. K. (2018 ). Total Synthesis of (-)-Mucosin and Revision of Structure. J. Org. Chem. 83,15066–15076.
Not in our library10.1021/acs.joc.8b02318
304.
Nosjean O. Ferro M. Coge F. Beauverger P. Henlin J. M. Lefoulon F. (2000 ). Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem. 275, 31311–31317.
Not in our library10.1074/jbc.m005141200
305.
Nothias L.-F. Boutet-Mercey S. Cachet X. La Torre E. Laboureur L. Gallard J.-F. (2017 ). Environmentally Friendly Procedure Based on Supercritical Fluid Chromatography and Tandem Mass Spectrometry Molecular Networking for the Discovery of Potent Antiviral Compounds from Euphorbia semiperfoliata. J. Natural Prod. 80, 2620–2629.
Not in our library10.1021/acs.jnatprod.7b00113
306.
Nothias L.-F. Nothias-Esposito M. da Silva R. Wang M. Protsyuk I. Zhang Z. (2018 ). Bioactivity-Based Molecular Networking for the Discovery of Drug Leads in Natural Product Bioassay-Guided Fractionation. J. Natural Prod. 81, 758–767.
Not in our library10.1021/acs.jnatprod.7b00737
307.
Noumeur S. R. Helaly S. E. Jansen R. Gereke M. Stradal T. E. B. Harzallah D. (2017 ). Preussilides A-F, Bicyclic Polyketides from the Endophytic Fungus Preussia similis with Antiproliferative Activity. J. Natural Prod. 80, 1531–1540.
Not in our library10.1021/acs.jnatprod.7b00064
308.
Novakovic M. Nikodinovic-Runic J. Veselinovic J. Ilic-Tomic T. Vidakovic V. Tesevic V. (2017 ). Bioactive Pentacyclic Triterpene Ester Derivatives from Alnus viridis ssp. viridis Bark. J. Natural Prod. 80, 1255–1263.
Not in our library10.1021/acs.jnatprod.6b00805
309.
Ntumba J. K. Tshiongo C. M. Mifundu M. N. Robiette R. Taba K. M. (2018 ). Effective Antimalarial Activities of α-Hydroxy Diynes Isolated from Ongokea gore. Planta Med. 84, 806–812.
Not in our library10.1055/s-0043-124974
310.
Nur-E-Alam M. Yousaf M. Ahmed S. Al-Sheddi E. S. Parveen I. Fazakerley D. M. (2017 ). Neoclerodane Diterpenoids from Reehal Fatima, Teucrium yemense. J. Natural Prod. 80, 1900–1908.
Not in our library10.1021/acs.jnatprod.7b00188
311.
Nyandoro S. S. Munissi J. J. E. Gruhonjic A. Duffy S. Pan F. Puttreddy R. (2017 a). Polyoxygenated Cyclohexenes and Other Constituents of Cleistochlamys kirkii Leaves. J. Natural Prod. 80, 114–125.
Not in our library10.1021/acs.jnatprod.6b00759
312.
Nyandoro S. S. Munissi J. J. E. Kombo M. Mgina C. A. Pan F. Gruhonjic A. (2017 b). Flavonoids from Erythrina schliebenii. J. Natural Prod. 80, 377–383.
Not in our library10.1021/acs.jnatprod.6b00839
313.
Nzogong R. T. Nganou B. K. Tedonkeu A. T. Awouafack M. D. Tene M. Ito T. (2018 ). Three New Abietane-Type Diterpenoids from Plectranthus africanus and Their Antibacterial Activities. Planta Med. 84, 59–64.
Not in our library10.1055/s-0043-114426
314.
Ochoa-Villarreal M. Howat S. Jang M. O. Kim I. S. Jin Y.-W. Lee E.-K. (2015 ). Cambial meristematic cells: a platform for the production of plant natural products. New Biotechnol. 32, 581–587.
Not in our library10.1016/j.nbt.2015.02.003
315.
Oghumu S. Varikuti S. Saljoughian N. Terrazas C. Huntsman A. C. Parinandi N. L. (2017 ). Pentalinonsterol, a Constituent of Pentalinon andrieuxii, Possesses Potent Immunomodulatory Activity and Primes T Cell Immune Responses. J. Natural Prod. 80, 2515–2523.
Not in our library10.1021/acs.jnatprod.7b00445
316.
Ogihara T. Amano N. Mitsui Y. Fujino K. Ohta H. Takahashi K. (2017 ). Determination of the Absolute Configuration of a Monoglyceride Antibolting Compound and Isolation of Related Compounds from Radish Leaves (Raphanus sativus). J. Natural Prod. 80, 872–878.
Not in our library10.1021/acs.jnatprod.6b00746
317.
Oksman-Caldentey K.-M. Saito K. (2005 ). Integrating genomics and metabolomics for engineering plant metabolic pathways. Curr. Opin. Biotechnol. 16, 174–179.
Not in our library10.1016/j.copbio.2005.02.007
318.
Oliveira M. Rodrigues M. J. Pereira C. Neto R. Junior P. A. S. Neng N. (2018 ). First report of the in vitro antileishmanial properties of extremophile plants from the Algarve Coast. Natural Prod. Res. 32, 600–604.
Not in our library10.1080/14786419.2017.1326489
319.
Olivon F. Nothias L.-F. Dumontet V. Retailleau P. Berger S. Ferry G. (2018 ). Natural Inhibitors of the RhoA-p115 Complex from the Bark of Meiogyne baillonii. J. Natural Prod. 81, 1610–1618.
Not in our library10.1021/acs.jnatprod.8b00209
320.
Orellana R. Macaya C. Bravo G. Dorochesi F. Cumsille A. Valencia R. (2018 ). Living at the Frontiers of Life: Extremophiles in Chile and Their Potential for Bioremediation. Front. Microbiol. 9, 2309.
Not in our library10.3389/fmicb.2018.02309
321.
Owen C. Patron N. J. Huang A. Osbourn A. (2017 ). Harnessing plant metabolic diversity. Curr. Opin. Chem. Biol. 40, 24–30.
Not in our library10.1016/j.cbpa.2017.04.015
322.
Paddon C. J. Keasling J. D. (2014 ). Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development. Nat. Rev. Microbiol. 12, 355–367.
Not in our library10.1038/nrmicro3240
323.
Pantin M. Brimble M. A. Furkert D. P. (2018 ). Total Synthesis of (-)-Peniphenone A. J. Org. Chem. 83, 7049–7059.
Not in our library10.1021/acs.joc.7b03231
324.
Parrot D. Papazian S. Foil D. Tasdemir D. (2018 ). Imaging the Unimaginable: Desorption Electrospray Ionization - Imaging Mass Spectrometry (DESI-IMS) in Natural Product Research. Planta Med. 84, 584–593.
Not in our library10.1055/s-0044-100188
325.
Patel S. (2016 ). Salicornia: Evaluating the halophytic extremophile as a food and a pharmaceutical candidate. 3 Biotech. 6, 104.
Not in our library10.1007/s13205-016-0418-6
326.
Peng R. VanNieuwenhze M. S. (2019 ). Studies towards the Total Synthesis of Nogalamycin: Construction of the Complete ABCDEF-ring System via a Convergent Hauser Annulation. J. Org. Chem. 84, 760–768.
Not in our library10.1021/acs.joc.8b02602
327.
Peresse T. Jezequel G. Allard P.-M. Pham V.-C. Huong D. T. M. Blanchard F. (2017 ). Cytotoxic Prenylated Stilbenes Isolated from Macaranga tanarius. J. Natural Prod. 80, 2684–2691.
Not in our library10.1021/acs.jnatprod.7b00409
328.
Pérez-Colmenares A. Obregón-Díaz Y. Rojas-Fermín L. Aparicio-Zambrano R. Carmona-Arzola J. Usubillaga A. (2018 ). Chemical Composition of the Essential Oil of Phyllanthus acidus. Natural Prod. Commun. 13, 97–98.
Not in our library10.1177/1934578x1801300128
329.
Pham A. T. Malterud K. E. Paulsen B. S. Diallo D. Wangensteen H. (2014 ). alpha-Glucosidase inhibition, 15-lipoxygenase inhibition, and brine shrimp toxicity of extracts and isolated compounds from Terminalia macroptera leaves. Pharm. Biol. 52, 1166–1169.
Not in our library10.3109/13880209.2014.880486
330.
Qi C. Wang W. Reichl K. D. McNeely J. Porco J. A. J. R. (2018 ). Total Synthesis of Aurofusarin: Studies on the Atropisomeric Stability of Bis-Naphthoquinones. Angew. Che. (Int. Ed. English) 57, 2101–2104.
Not in our library10.1002/anie.201711535
331.
Qin X.-J. Zhi Y.-E. Yan H. Zhang Y. Liu H. Yu Q. (2018 ). Baeckfrutones A–L, polymethylated phloroglucinol meroterpenoids from the twigs and leaves of Baeckea frutescens. Tetrahedron 74, 6658–6666.
Not in our library10.1016/j.tet.2018.09.050
332.
Qiu S. Yang W.-Z. Yao C.-L. Shi X.-J. Li J.-Y. Lou Y. (2017 ). Malonylginsenosides with Potential Antidiabetic Activities from the Flower Buds of Panax ginseng. J. Natural Prod. 80, 899–908.
Not in our library10.1021/acs.jnatprod.6b00789
333.
Quinn R. J. Carroll A. R. Pham N. B. Baron P. Palframan M. E. Suraweera L. (2008 ). Developing a drug-like natural product library. J. Nat. Prod. (Gorakhpur) 71, 464–468.
Not in our library10.1021/np070526y
334.
Rédei D. Kúsz N. Sátori G. Kincses A. Spengler G. Burián K. (2018 ). Bioactive Segetane, Ingenane, and Jatrophane Diterpenes from Euphorbia taurinensis. Planta Med. 84, 729–735.
Not in our library10.1055/a-0589-0525
335.
Rahimzadeh M. Jahanshahi S. Moein S. Moein M. R. (2014 ). Evaluation of alpha- amylase inhibition by Urtica dioica and Juglans regia extracts. Iran. J. Basic Med. Sci. 17, 465–469.
Not in our library
336.
Ramalhete C. Mulhovo S. Lage H. Ferreira M.-J. U. (2018 ). Triterpenoids from Momordica balsamina with a Collateral Sensitivity Effect for Tackling Multidrug Resistance in Cancer Cells. Planta Med. 84, 1372–1379.
Not in our library10.1055/a-0651-8141
337.
Ramseyer J. Thuerig B. Mieri M. Scharer H.-J. Oberhansli T. Gupta M. P. (2017 ). Eudesmane Sesquiterpenes from Verbesina lanata with Inhibitory Activity against Grapevine Downy Mildew. J. Natural Prod. 80, 3296–3304.
Not in our library10.1021/acs.jnatprod.7b00868
338.
Rangel-Grimaldo M. Rivero-Cruz I. Madariaga-Mazon A. Figueroa M. Mata R. (2017 ). alpha-Glucosidase Inhibitors from Preussia minimoides double dagger. J. Natural Prod. 80, 582–587.
Not in our library10.1021/acs.jnatprod.6b00574
339.
Raut A. A. Chorghade M. S. Vaidya A. D. B. (2017 ). “Reverse Pharmacology,” in Innovative approaches in drug discovery: Ethnopharmacology, systems biology and holistic targeting. Eds. Patwardhan B. Chaguturu R. (London: Academic Press), 89–126.
Not in our library
340.
A translational synthetic biology platform for rapid access to gram-scale quantities of novel drug-like molecules · 2017
No notice
341.
Reid B. T. Mailyan A. K. Zakarian A. (2018 ). Total Synthesis of (+)-Guadinomic Acid via Hydroxyl-Directed Guanidylation. J. Org. Chem. 83, 9492–9496.
Not in our library10.1021/acs.joc.8b01214
342.
Ren J. Ding S.-S. Zhu A. Cao F. Zhu H.-J. (2017 ). Bioactive Azaphilone Derivatives from the Fungus Talaromyces aculeatus. J. Natural Prod. 80, 2199–2203.
Not in our library10.1021/acs.jnatprod.7b00032
343.
Ren Y. Chen W.-L. Lantvit D. D. Sass E. J. Shriwas P. Ninh T. N. (2017 ). Cardiac Glycoside Constituents of Streblus asper with Potential Antineoplastic Activity. J. Natural Prod. 80, 648–658.
Not in our library10.1021/acs.jnatprod.6b00924
344.
Richter M. J. R. Schneider M. Brandstatter M. Krautwald S. Carreira E. M. (2018 ). Total Synthesis of (-)-Mitrephorone A. J. Am. Chem. Soc. 140, 16704–16710
Not in our library10.1021/jacs.8b09685
345.
Riemer M. Uzunova V. V. Riemer N. Clarkson G. J. Pereira N. Napier R. (2018 ). Phyllostictine A: total synthesis, structural verification and determination of substructure responsible for plant growth inhibition. Chem. Commun. (Cambridge England) 54, 7211–7214.
Not in our library10.1039/c8cc03349h
346.
Rios M. Y. Navarro V. Ramirez-Cisneros M. A. Salazar-Rios E. (2017 ). Sulfur-Containing Aristoloxazines and Other Constituents of the Roots of Aristolochia orbicularis. J. Natural Prod. 80, 3112–3119.
Not in our library10.1021/acs.jnatprod.7b00226
347.
Robertson L. P. Duffy S. Wang Y. Wang D. Avery V. M. Carroll A. R. (2017 ). Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana. J. Natural Prod. 80, 3211–3217.
Not in our library10.1021/acs.jnatprod.7b00587
348.
Rodrigues T. Reker D. Schneider P. Schneider G. (2016 ). Counting on natural products for drug design. Nat. Chem. 8, 531–541.
Not in our library10.1038/nchem.2479
349.
Rosén J. Gottfries J. Muresan S. Backlund A. Oprea T. I. (2009 a). Novel chemical space exploration via natural products. J. Med. Chem. 52, 1953–1962.
Not in our library10.1021/jm801514w
350.
Rosén J. Lövgren A. Kogej T. Muresan S. Gottfries J. Backlund A. (2009 b). ChemGPS-NP(Web): chemical space navigation online. J. Comput. Aided Mol. Des. 23, 253–259.
Not in our library10.1007/s10822-008-9255-y
351.
Ross I. A. (1999 ). Medicinal plants of the world Part 1: Chemical constituents, traditional and modern medicinal uses (Totowa, New Jersey: Humana Press).
Not in our library
352.
Ross I. A. (2001 ). Medicinal plants of the world Part 2: Chemical constituents, traditional and modern medicinal uses (Totowa (N.J.): Humana Press).
Not in our library
353.
Roy A. Bharadvaja N. (2018 ). Biotechnological Approaches for the Production of Pharmaceutically Important Compound: Plumbagin. CPB 19, 372–381.
Not in our library10.2174/1389201019666180629143842
354.
Rulliere P. Cannillo A. Grisel J. Cividino P. Sebastien C. Poisson J.-F. (2018 ). Total Synthesis of Proteasome Inhibitor (-)-Omuralide through Asymmetric Ketene 2 + 2-Cycloaddition. Org. Lett. 20, 4558–4561.
Not in our library10.1021/acs.orglett.8b01851
355.
Ryu H. W. Park Y. J. Lee S. U. Lee S. Yuk H. J. Seo K.-H. (2017 ). Potential Anti-inflammatory Effects of the Fruits of Paulownia tomentosa. J. Natural Prod. 80, 2659–2665.
Not in our library10.1021/acs.jnatprod.7b00325
356.
Saad K. R. Parvatam G. Shetty N. P. (2018 ). Medium composition potentially regulates the anthocyanin production from suspension culture of Daucus carota. 3 Biotech. 8, 134.
Not in our library10.1007/s13205-018-1146-x
357.
Sahraroo A. Babalar M. Mirjalili M. H. Fattahi Moghaddam M. R. Nejad Ebrahimi S. (2014 ). In-vitro Callus Induction and Rosmarinic Acid Quantification in Callus Culture of Satureja khuzistanica Jamzad (Lamiaceae). Iran. J. Pharm. Res.: IJPR 13, 1447–1456.
Not in our library
358.
Salah El Dine R. Abdallah H. M. Kandil Z. A. Zaki A. A. Khan S. I. Khan I. A. (2019 ). PPARα and γ Activation Effects of New Nor-triterpenoidal Saponins from the Aerial Parts of Anabasis articulata. Planta Med. 85, 274–281.
Not in our library10.1055/a-0762-0885
359.
Saleem H. Ahmad I. Shahid M. N. Gill M. S. A. Nadeem M. F. Mahmood W. (2016 ). In Vitro Acetylcholinesterase And Butyrylcholinesterase Inhibitory Potentials Of Jatropha Gossypifolia Plant Extracts. Acta Pol. Pharm. 73, 419–423.
Not in our library
360.
Samala M. Lu T. N. Mandava S. Hwang J. Bogonda G. Kim D. (2018 ). Stereoselective Protection-Free Asymmetric Total Synthesis of (+)-Chamuvarinin, a Potent Anticancer and Antitrypanosomal Agent: Substrate-Controlled Construction of the Adjacently Linked Oxatricyclic Core by Internal Alkylation. Org. Lett. 20, 6398–6402.
Not in our library10.1021/acs.orglett.8b02706
361.
Sangwan N. S. Farooqi A. H. A. Shabih F. Sangwan R. S. (2001 ). Regulation of essential oil production in plants. Plant Growth Regul. 34, 3–21.
Not in our library10.1023/a:1013386921596
362.
Sarker S. D. Nahar L. (2012 ). Natural Products Isolation (Totowa, NJ: Humana Press).
Not in our library
363.
Cold and Hot Extremozymes: Industrial Relevance and Current Trends · 2015
No notice
364.
Saya J. M. Roose T. R. Peek J. J. Weijers B. Waal D. E Thomas J. S. (2018 ). Iodospirocyclization of Tryptamine-Derived Isocyanides: Formal Total Synthesis of Aspidofractinine. Angew. Che. (Int. Ed. English) 57, 15232–15236.
Not in our library10.1002/anie.201809678
365.
Schloss S. Hackl T. Herz C. Lamy E. Koch M. Rohn S. (2017 ). Detection of a Toxic Methylated Derivative of Phomopsin A Produced by the Legume-Infesting Fungus Diaporthe toxica. J. Natural Prod. 80, 1930–1934.
Not in our library10.1021/acs.jnatprod.6b00662
366.
Schmid Sattler Grabley Thiericke (1999 ). Natural Products in High Throughput Screening: Automated High-Quality Sample Preparation. J. Biomol. Screen 4, 15–25.
Not in our library10.1177/108705719900400104
367.
Schuman M. C. van Dam N. M. Beran F. Harpole W. S. (2016 ). How does plant chemical diversity contribute to biodiversity at higher trophic levels? Curr. Opin. Insect Sci. 14, 46–55.
Not in our library10.1016/j.cois.2016.01.003
368.
Schwikkard S. Alqahtani A. Knirsch W. Wetschnig W. Jaksevicius A. Opara E. I. (2017 ). Phytochemical Investigations of Three Rhodocodon (Hyacinthaceae Sensu APG II) Species. J. Natural Prod. 80, 30–37.
Not in our library10.1021/acs.jnatprod.6b00240
369.
Scossa F. Benina M. Alseekh S. Zhang Y. Fernie A. R. (2018 ). The Integration of Metabolomics and Next-Generation Sequencing Data to Elucidate the Pathways of Natural Product Metabolism in Medicinal Plants. Planta Med. 84, 855–873.
Not in our library10.1055/a-0630-1899
370.
Seeka C. Prabpai S. Kongsaeree P. Tewtrakul S. Lhinhatrakool T. Sutthivaiyakit S. (2017 ). Anti-inflammatory 12,20-Epoxypregnane and 11,12-seco-Pregnane Glycosides from the Stems of Hoya kerrii. J. Natural Prod. 80, 1714–1724.
Not in our library10.1021/acs.jnatprod.6b00730
371.
Sendker J. Boker I. Lengers I. Brandt S. Jose J. Stark T. (2017 ). Phytochemical Characterization of Low Molecular Weight Constituents from Marshmallow Roots (Althaea officinalis) and Inhibiting Effects of the Aqueous Extract on Human Hyaluronidase-1. J. Natural Prod. 80, 290–297.
Not in our library10.1021/acs.jnatprod.6b00670
372.
Shaaban K. A. Saunders M. A. Zhang Y. Tran T. Elshahawi S. I. Ponomareva L. V. (2017 ). Spoxazomicin D and Oxachelin C, Potent Neuroprotective Carboxamides from the Appalachian Coal Fire-Associated Isolate Streptomyces sp. RM-14-6. J. Natural Prod. 80, 2–11.
Not in our library10.1021/acs.jnatprod.6b00948
373.
Shapiro J. A. Morrison K. R. Chodisetty S. S. Musaev D. G. Wuest W. M. (2018 ). Biologically Inspired Total Synthesis of Ulbactin F, an Iron-Binding Natural Product. Org. Lett. 20, 5922–5926.
Not in our library10.1021/acs.orglett.8b02599
374.
Sharma S. B. Gupta R. (2015 ). Drug development from natural resource: a systematic approach. Mini Rev. Med. Chem. 15, 52–57.
Not in our library10.2174/138955751501150224160518
375.
Sharma R. Gatchie L. Williams I. S. Jain S. K. Vishwakarma R. A. Chaudhuri B. (2017 ). Glycyrrhiza glabra extract and quercetin reverses cisplatin resistance in triple-negative MDA-MB-468 breast cancer cells via inhibition of cytochrome P450 1B1 enzyme. Bioorg. Med. Chem. Lett. 27, 5400–5403.
Not in our library10.1016/j.bmcl.2017.11.013
376.
Sharma R. Williams I. S. Gatchie L. Sonawane V. R. Chaudhuri B. Bharate S. B. (2018 ). Furanoflavones pongapin and lanceolatin B blocks the cell cycle and induce senescence in CYP1A1-overexpressing breast cancer cells. Bioorg. Med. Chem. 26, 6076–6086.
Not in our library10.1016/j.bmc.2018.11.013
377.
Shi D.-H. Xu C. Guo B.-X. Wang X.-T. Chen Y.-X. Tan R.-X. (2008 ). Inhibition of soluble epoxide hydrolase by extracts derived from inflammation-treating Chinese medicinal herbs. Phytother. Res.: PTR 22, 1264–1268.
Not in our library10.1002/ptr.2326
378.
Shimozu Y. Kuroda T. Tsuchiya T. Hatano T. (2017 ). Structures and Antibacterial Properties of Isorugosins H-J, Oligomeric Ellagitannins from Liquidambar formosana with Characteristic Bridging Groups between Sugar Moieties. J. Natural Prod. 80, 2723–2733.
Not in our library10.1021/acs.jnatprod.7b00496
379.
Shin S. H. Lee S. R. Lee E. Kim K. H. Byun S. (2017 ). Caffeic Acid Phenethyl Ester from the Twigs of Cinnamomum cassia Inhibits Malignant Cell Transformation by Inducing c-Fos Degradation. J. Natural Prod. 80, 2124–2130.
Not in our library10.1021/acs.jnatprod.7b00433
380.
Sibi G. (2015 ). Inhibition of lipase and inflammatory mediators by Chlorella lipid extracts for antiacne treatment. J. Adv. Pharm. Technol. Res. 6, 7–12.
Not in our library10.4103/2231-4040.150364
381.
Sidjui L. S. Eyong K. O. Hull K. G. Folefoc G. N. Leddet V. M. Herbette G. (2017 ). Bioactive Seco-Lanostane-Type Triterpenoids from the Roots of Leplaea mayombensis. J. Natural Prod. 80, 2644–2651.
Not in our library10.1021/acs.jnatprod.7b00210
382.
Silva G. H. Zeraik M. L. Oliveira C. M. Teles H. L. Trevisan H. C. Pfenning L. H. (2017 ). Lactone Derivatives Produced by a Phaeoacremonium sp., an Endophytic Fungus from Senna spectabilis. J. Natural Prod. 80, 1674–1678.
Not in our library10.1021/acs.jnatprod.5b00828
383.
Sirtori C. R. (2014 ). The pharmacology of statins. Pharmacol. Res. 88, 3–11.
Not in our library10.1016/j.phrs.2014.03.002
384.
Skinnider M. A. Dejong C. A. Franczak B. C. McNicholas P. D. Magarvey N. A. (2017 ). Comparative analysis of chemical similarity methods for modular natural products with a hypothetical structure enumeration algorithm. J. Cheminform. 9, 46.
Not in our library10.1186/s13321-017-0234-y
385.
Smanski M. J. Zhou H. Claesen J. Shen B. Fischbach M. A. Voigt C. A. (2016 ). Synthetic biology to access and expand nature’s chemical diversity. Nat. Rev. Microbiol. 14, 135–149.
Not in our library10.1038/nrmicro.2015.24
386.
Soares A. S. Barbosa F. L. Rudiger A. L. Hughes D. L. Salvador M. J. Zampronio A. R. (2017 ). Naphthoquinones of Sinningia reitzii and Anti-inflammatory/Antinociceptive Activities of 8-Hydroxydehydrodunnione. J. Natural Prod. 80, 1837–1843.
Not in our library10.1021/acs.jnatprod.6b01186
387.
Solyomváry A. Beni S. Boldizsar I. (2017 ). Dibenzylbutyrolactone Lignans - A Review of Their Structural Diversity, Biosynthesis, Occurrence, Identification and Importance. Mini Rev. Med. Chem. 17, 1053–1074.
Not in our library10.2174/1389557516666160614005828
388.
Sribuhom T. Boueroy P. Hahnvajanawong C. Phatchana R. Yenjai C. (2017 ). Benzoyltyramine Alkaloids Atalantums A-G from the Peels of Atalantia monophylla and Their Cytotoxicity against Cholangiocarcinoma Cell Lines. J. Natural Prod. 80, 403–408.
Not in our library10.1021/acs.jnatprod.6b00908
389.
Sriyatep T. Andersen R. J. Patrick B. O. Pyne S. G. Muanprasat C. Seemakhan S. (2017 ). Scalemic Caged Xanthones Isolated from the Stem Bark Extract of Garcinia propinqua. J. Natural Prod. 80, 1658–1667.
Not in our library10.1021/acs.jnatprod.7b00240
390.
Starkus J. G. Poerzgen P. Layugan K. Kawabata K. G. Goto J.-I. Suzuki S. (2017 ). Scalaradial Is a Potent Inhibitor of Transient Receptor Potential Melastatin 2 (TRPM2) Ion Channels. J. Natural Prod. 80, 2741–2750.
Not in our library10.1021/acs.jnatprod.7b00515
391.
St-Pierre A. Blondeau D. Lajeunesse A. Bley J. Bourdeau N. Desgagné-Penix I. (2018 ). Phytochemical Screening of Quaking Aspen (Populus tremuloides) Extracts by UPLC-QTOF-MS and Evaluation of their Antimicrobial Activity. Molecules 23, 1739.
Not in our library10.3390/molecules23071739
392.
Suarez-Ortiz G. A. Cerda-Garcia-Rojas C. M. Fragoso-Serrano M. Pereda-Miranda R. (2017 ). Complementarity of DFT Calculations, NMR Anisotropy, and ECD for the Configurational Analysis of Brevipolides K-O from Hyptis brevipes. J. Natural Prod. 80, 181–189.
Not in our library10.1021/acs.jnatprod.6b00953
393.
Suh W. S. Kim C. S. Subedi L. Kim S. Y. Choi S. U. Lee K. R. (2017 ). Iridoid Glycosides from the Twigs of Sambucus williamsii var. coreana and Their Biological Activities. J. Natural Prod. 80, 2502–2508.
Not in our library10.1021/acs.jnatprod.7b00410
394.
Surapinit S. Sichaem J. Tip-Pyang S. (2018 ). Non-redox Lipoxygenase Inhibitors from Nauclea orientalis. Natural Prod. Commun. 13, 33–36.
Not in our library10.1177/1934578x1801300111
395.
Suzuki A. Saito Y. Fukuyoshi S. Goto M. Miyake K. Newman D. J. (2017 ). Corymbulosins D-H, 2-Hydroxy- and 2-Oxo-clerodane Diterpenes from the Bark of Laetia corymbulosa. J. Natural Prod. 80, 1065–1072.
Not in our library10.1021/acs.jnatprod.6b01151
396.
Szopa A. Kokotkiewicz A. Luczkiewicz M. Ekiert H. (2017 ). Schisandra lignans production regulated by different bioreactor type. J. Biotechnol. 247, 11–17.
Not in our library10.1016/j.jbiotec.2017.02.007
397.
Szopa A. Klimek-Szczykutowicz M. Kokotkiewicz A. Maślanka A. Król A. Luczkiewicz M. (2018 ). Phytochemical and biotechnological studies on Schisandra chinensis cultivar Sadova No. 1-a high utility medicinal plant. Appl. Microbiol. Biotechnol. 102, 5105–5120.
Not in our library10.1007/s00253-018-8981-x
398.
Tabefam M. Farimani M. M. Danton O. Ramseyer J. Kaiser M. Ebrahimi S. N. (2018 ). Antiprotozoal Diterpenes from Perovskia abrotanoides. Planta Med. 84, 913–919.
Not in our library10.1055/a-0608-4946
399.
Tarazona G. Schleissner C. Rodriguez P. Perez M. Canedo L. M. Cuevas C. (2017 ). Streptenols F-I Isolated from the Marine-Derived Streptomyces misionensis BAT-10-03-023. J. Natural Prod. 80, 1034–1038.
Not in our library10.1021/acs.jnatprod.6b01057
400.
Teta R. Marteinsson V. T. Longeon A. Klonowski A. M. Groben R. Bourguet-Kondracki M.-L. (2017 ). Thermoactinoamide A, an Antibiotic Lipophilic Cyclopeptide from the Icelandic Thermophilic Bacterium Thermoactinomyces vulgaris. J. Natural Prod. 80, 2530–2535.
Not in our library10.1021/acs.jnatprod.7b00560
401.
Thao N. P. Luyen B. T. T. Lee J. S. Kim J. H. Dat N. T. Kim Y. H. (2017 ). Inhibition Potential of Cycloartane-Type Glycosides from the Roots of Cimicifuga dahurica against Soluble Epoxide Hydrolase. J. Natural Prod. 80, 1867–1875.
Not in our library10.1021/acs.jnatprod.7b00166
402.
The Angiosperm Phylogeny GroupChase M. W. Christenhusz M. J. M. Fay M. F. Byng J. W. Judd W. S. (2016 ). An update of the Angiosperm Phylogeny Group classification for the orders and families of flowering plants: APG IV. Bot. J. Linn. Soc 181, (1), 1–20.
Not in our library10.1111/boj.12385
403.
Thiericke R. (2000 ). Drug discovery from nature: Automated high-quality sample preparation. J. Autom. Methods Manage. Chem. 22, 149–157.
Not in our library10.1155/s1463924600000249
404.
Thornburg C. C. Britt J. R. Evans J. R. Akee R. K. Whitt J. A. Trinh S. K. (2018 ). NCI Program for Natural Product Discovery: A Publicly-Accessible Library of Natural Product Fractions for High-Throughput Screening. ACS Chem. Biol. 13, 2484–2497.
Not in our library10.1021/acschembio.8b00389
405.
Torii M. Kato H. Hitora Y. Angkouw E. D. Mangindaan R. E. P. Voogd N. J. (2017 ). Lamellodysidines A and B, Sesquiterpenes Isolated from the Marine Sponge Lamellodysidea herbacea. J. Natural Prod. 80, 2536–2541.
Not in our library10.1021/acs.jnatprod.7b00610
406.
Trethewey R. N. (2004 ). Metabolite profiling as an aid to metabolic engineering in plants. Curr. Opin. Plant Biol. 7, 196–201.
Not in our library10.1016/j.pbi.2003.12.003
407.
Trosset J.-Y. Carbonell P. (2015 ). Synthetic biology for pharmaceutical drug discovery. Drug Des. Dev. Ther. 9, 6285–6302.
Not in our library10.2147/dddt.s58049
408.
Tsepaeva O. V. Nemtarev A. V. Abdullin T. I. Grigor’eva L. R. Kuznetsova E. V. Akhmadishina R. A. (2017 ). Design, Synthesis, and Cancer Cell Growth Inhibitory Activity of Triphenylphosphonium Derivatives of the Triterpenoid Betulin. J. Natural Prod. 80, 2232–2239.
Not in our library10.1021/acs.jnatprod.7b00105
409.
Tshitenge D. T. Feineis D. Awale S. Bringmann G. (2017 ). Gardenifolins A-H, Scalemic Neolignans from Gardenia ternifolia: Chiral Resolution, Configurational Assignment, and Cytotoxic Activities against the HeLa Cancer Cell Line. J. Natural Prod. 80, 1604–1614.
Not in our library10.1021/acs.jnatprod.7b00180
410.
Tsukamoto H. Hanada S. Nomura Y. Doi T. (2018 ). Total Synthesis of Spiromamakone A and Structure Revision of Spiropreussione A. J. Org. Chem. 83, 9430–9441.
Not in our library10.1021/acs.joc.8b01075
411.
Tuan N. Q. Lee D.-H. Oh J. Kim C. S. Heo K.-S. Myung C.-S. (2017 ). Inhibition of Proliferation of Vascular Smooth Muscle Cells by Cucurbitanes from Momordica charantia. J. Natural Prod. 80, 2018–2025.
Not in our library10.1021/acs.jnatprod.7b00151
412.
Turumtay H. Midilli A. Turumtay E. A. Demir A. Selvi E. K. Budak E. E. (2017 ). Gram (-) microorganisms DNA polymerase inhibition, antibacterial and chemical properties of fruit and leaf extracts of Sorbus acuparia and Sorbus caucasica var. yaltirikii. Biomed. Chromatogr. BMC 31.
Not in our library10.1002/bmc.3901
413.
Twigg D. G. Baldassarre L. Frye E. C. Galloway Warren R. J. D. Spring D. R. (2018 ). Bioinspired Total Synthesis of Bussealin E. Org. Lett. 20, 1597–1599.
Not in our library10.1021/acs.orglett.8b00340
414.
Umeno D. Tobias A. V. Arnold F. H. (2005 ). Diversifying carotenoid biosynthetic pathways by directed evolution. Microbiol. Mol. Biol. Rev.: MMBR 69, 51–78.
Not in our library10.1128/mmbr.69.1.51-78.2005
415.
Valencia-Chan L. S. Garcia-Camara I. Torres-Tapia L. W. Moo-Puc R. E. Peraza-Sanchez S. R. (2017 ). Lupane-Type Triterpenes of Phoradendron vernicosum. J. Natural Prod. 80, 3038–3042.
Not in our library10.1021/acs.jnatprod.7b00177
416.
Vallisuta O. Nukoolkarn V. Mitrevej A. Sarisuta N. Leelapornpisid P. Phrutivorapongkul A. (2014 ). In vitro studies on the cytotoxicity, and elastase and tyrosinase inhibitory activities of marigold (Tagetes erecta L.) flower extracts. Exp. Ther. Med. 7, 246–250.
Not in our library10.3892/etm.2013.1373
417.
Verardo G. Gorassini A. Ricci D. Fraternale D. (2017 ). High Triterpenic Acids Production in Callus Cultures from Fruit Pulp of Two Apple Varieties. Phytochem. Anal. 28, 5–15.
Not in our library10.1002/pca.2638
418.
Verastegui-Omana B. Rebollar-Ramos D. Perez-Vasquez A. Martinez A. L. Madariaga-Mazon A. Flores-Bocanegra L. (2017 ). alpha-Glucosidase Inhibitors from Malbranchea flavorosea. J. Natural Prod. 80, 190–195.
Not in our library10.1021/acs.jnatprod.6b00977
419.
Wagh V. D. Korinek M. Lo I.-W. Hsu Y.-M. Chen S.-L. Hsu H.-Y. (2017 ). Inflammation Modulatory Phorbol Esters from the Seeds of Aquilaria malaccensis. J. Natural Prod. 80, 1421–1427.
Not in our library10.1021/acs.jnatprod.6b01096
420.
Wang C.-J. Yan Q.-L. Ma Y.-F. Sun C.-P. Chen C.-M. Tian X.-G. (2017 ). ent-Abietane and Tigliane Diterpenoids from the Roots of Euphorbia fischeriana and Their Inhibitory Effects against Mycobacterium smegmatis. J. Natural Prod. 80, 1248–1254.
Not in our library10.1021/acs.jnatprod.6b00786
421.
Wang K.-B. Li D.-H. Bao Y. Cao F. Wang W.-J. Lin C. (2017 ). Structurally Diverse Alkaloids from the Seeds of Peganum harmala. J. Natural Prod. 80, 551–559.
Not in our library10.1021/acs.jnatprod.6b01146
422.
Wang L.-Y. Chen M.-H. Wu J. Sun H. Liu W. Qu Y.-H. (2017 ). Bioactive Glycosides from the Twigs of Litsea cubeba. J. Natural Prod. 80, 1808–1818.
Not in our library10.1021/acs.jnatprod.6b01189
423.
Wang X. Li L. Zhu R. Zhang J. Zhou J. Lou H. (2017 ). Bibenzyl-Based Meroterpenoid Enantiomers from the Chinese Liverwort Radula sumatrana. J. Natural Prod. 80, 3143–3150.
Not in our library10.1021/acs.jnatprod.7b00394
424.
Wang Y.-S. Li B.-T. Liu S.-X. Wen Z.-Q. Yang J.-H. Zhang H.-B. (2017 ). Anisucoumaramide, a Bioactive Coumarin from Clausena anisum-olens. J. Natural Prod. 80, 798–804.
Not in our library10.1021/acs.jnatprod.6b00391
425.
Wang J. Duan H. Wang Y. Pan B. Gao C. Gai C. (2017 a). ent-Strobane and ent-Pimarane Diterpenoids from Siegesbeckia pubescens. J. Natural Prod. 80, 19–29.
Not in our library10.1021/acs.jnatprod.6b00150
426.
Wang J. He W. Kong F. Tian X. Wang P. Zhou X. (2017 b). Ochracenes A-I, Humulane-Derived Sesquiterpenoids from the Antarctic Fungus Aspergillus ochraceopetaliformis. J. Natural Prod. 80, 1725–1733.
Not in our library10.1021/acs.jnatprod.6b00810
427.
Wang J. Mu F.-R. Jiao W.-H. Huang J. Hong L.-L. Yang F. (2017 c). Meroterpenoids with Protein Tyrosine Phosphatase 1B Inhibitory Activity from a Hyrtios sp. Marine Sponge. J. Natural Prod. 80, 2509–2514.
Not in our library10.1021/acs.jnatprod.7b00435
428.
Wang S.-L. Liao H.-R. Cheng M.-J. Shu C.-W. Chen C.-L. Chung M.-I. (2018 ). Four New 2-(2-Phenylethyl)-4H-chromen-4-one Derivatives from the Resinous Wood of Aquilaria sinensis and Their Inhibitory Activities on Neutrophil Pro-Inflammatory Responses. Planta Med. 84, 1340–1347.
Not in our library10.1055/a-0645-1437
429.
Wang X. Liu F. Yun J. Feng Z. Jiang J. Yang Y. (2018 ). Iron-Catalyzed Synthesis of the Hexahydrocyclopentacfuran Core and Concise Total Synthesis of Polyflavanostilbene B. Angew. Che. (Int. Ed. English) 57, 10127–10131.
Not in our library10.1002/anie.201804329
430.
Wang X. Du C. Hong B. Lei X. (2019 ). Total synthesis of (+/-)-antroquinonol. Org. Biomolec. Chem. 17, 1754–1757.
Not in our library10.1039/c8ob02494d
431.
Waratchareeyakul W. Hellemann E. Gil R. R. Chantrapromma K. Langat M. K. Mulholland D. A. (2017 ). Application of Residual Dipolar Couplings and Selective Quantitative NOE to Establish the Structures of Tetranortriterpenoids from Xylocarpus rumphii. J. Natural Prod. 80, 391–402.
Not in our library10.1021/acs.jnatprod.6b00906
432.
Waterman M. J. Nugraha A. S. Hendra R. Ball G. E. Robinson S. A. Keller P. A. (2017 ). Antarctic Moss Biflavonoids Show High Antioxidant and Ultraviolet-Screening Activity. J. Natural Prod. 80, 2224–2231.
Not in our library10.1021/acs.jnatprod.7b00085
433.
Wei T. Dixon D. J. (2018 ). Catalytic stereoselective total synthesis of a spiro-oxindole alkaloid and the pentacyclic core of tryptoquivalines. Chem. Commun. (Cambridge England) 54, 12860–12862.
Not in our library10.1039/c8cc07479h
434.
Wei Y. Wang C. Cheng Z. Tian X. Jia J. Cui Y. (2017 ). Heterodimeric Diterpenoids Isolated from Euphorbia ebracteolata Roots and Their Inhibitory Effects on alpha-Glucosidase. J. Natural Prod. 80, 3218–3223.
Not in our library10.1021/acs.jnatprod.7b00595
435.
Weller M. G. (2012 ). A unifying review of bioassay-guided fractionation, effect-directed analysis and related techniques. Sensors 12, 9181–9209.
Not in our library10.3390/s120709181
436.
Wibowo M. Wang Q. Holst J. White J. M. Hofmann A. Davis R. A. (2017 ). Celastrofurans A-G: Dihydro-beta-agarofurans from the Australian Rainforest Vine Celastrus subspicata and Their Inhibitory Effect on Leucine Transport in Prostate Cancer Cells. J. Natural Prod. 80, 1918–1925.
Not in our library10.1021/acs.jnatprod.7b00220
437.
Wilson S. A. Roberts S. C. (2012 ). Recent advances towards development and commercialization of plant cell culture processes for the synthesis of biomolecules. Plant Biotechnol. J. 10, 249–268.
Not in our library10.1111/j.1467-7652.2011.00664.x
438.
Wolfender J.-L. Nuzillard J.-M. van der Hooft J. J. J. Renault J.-H. Bertrand S. (2019 ). Accelerating metabolite identification in natural product research: Toward an ideal combination of LC-HRMS/MS and NMR profiling, in silico databases and chemometrics. Analyt. Chem. 91, 704–742.
Not in our library10.1021/acs.analchem.8b05112
439.
Woo J.-K. Ha T. K. Q. Oh D.-C. Oh W.-K. Oh K.-B. Shin J. (2017 ). Polyoxygenated Steroids from the Sponge Clathria gombawuiensis. J. Natural Prod. 80, 3224–3233.
Not in our library10.1021/acs.jnatprod.7b00651
440.
Wu Y.-B. Wang Y.-Z. Ni Z.-Y. Qing X. Shi Q.-W. Sauriol F. (2017 ). Xylomexicanins I and J: Limonoids with Unusual B/C Rings from Xylocarpus granatum. J. Natural Prod. 80, 2547–2550.
Not in our library10.1021/acs.jnatprod.7b00305
441.
Xiao F. Li H. Xu M. Li T. Wang J. Sun C. (2018 ). Staurosporine Derivatives Generated by Pathway Engineering in a Heterologous Host and Their Cytotoxic Selectivity. J. Natural Prod. 81, 1745–1751.
Not in our library10.1021/acs.jnatprod.8b00103
442.
Xie T. Song S. Li S. Ouyang L. Xia L. Huang J. (2015 ). Review of natural product databases. Cell Proliferat. 48, 398–404.
Not in our library10.1111/cpr.12190
443.
Xie J. Wang Y. Jiang W.-W. Luo X.-F. Dai T.-Y. Peng L. (2018 ). Moringa oleifera Leaf Petroleum Ether Extract Inhibits Lipogenesis by Activating the AMPK Signaling Pathway. Front. Pharmacol. 9, 1447.
Not in our library10.3389/fphar.2018.01447
444.
Xiong J. Wan J. Ding J. Wang P.-P. Ma G.-L. Li J. (2017 ). Camellianols A-G, Barrigenol-like Triterpenoids with PTP1B Inhibitory Effects from the Endangered Ornamental Plant Camellia crapnelliana. J. Natural Prod. 80, 2874–2882.
Not in our library10.1021/acs.jnatprod.7b00241
445.
Xu L. Wu P. Xue J. Molnar I. Wei X. (2017 ). Antifungal and Cytotoxic beta-Resorcylic Acid Lactones from a Paecilomyces Species. J. Natural Prod. 80, 2215–2223.
Not in our library10.1021/acs.jnatprod.7b00066
446.
Xu S. Yao H. Hu M. Li D. Zhu Z. Xie W. (2017 ). 6,7-Seco-ent-Kauranoids Derived from Oridonin as Potential Anticancer Agents. J. Natural Prod. 80, 2391–2398.
Not in our library10.1021/acs.jnatprod.7b00057
447.
Xu Y.-M. Wijeratne E. M. K. Babyak A. L. Marks H. R. Brooks A. D. Tewary P. (2017 ). Withanolides from Aeroponically Grown Physalis peruviana and Their Selective Cytotoxicity to Prostate Cancer and Renal Carcinoma Cells. J. Natural Prod. 80, 1981–1991.
Not in our library10.1021/acs.jnatprod.6b01129
448.
Xu S. Wang G. Xu F. Li W. Lin A. Yao H. (2018 ). Concise Total Synthesis of (+/-)-Deguelin and (+/-)-Tephrosin Using a Vinyl Iodide as a Key Building Block. J. Natural Prod. 81, 1055–1059.
Not in our library10.1021/acs.jnatprod.7b00794
449.
Xue Y. Zhao P. Quan C. Zhao Z. Gao W. Li J. (2018 ). Cyanobacteria-derived peptide antibiotics discovered since 2000. Peptides 107, 17–24.
Not in our library10.1016/j.peptides.2018.08.002
450.
Yñigez-Gutierrez A. E. Bachmann B. O. (2019 ). Fixing the Unfixable: The Art of Optimizing Natural Products for Human Medicine. J. Med. Chem. 62, 8412–8428.
Not in our library10.1021/acs.jmedchem.9b00246
451.
Yadav D. K. Bharitkar Y. P. Hazra A. Pal U. Verma S. Jana S. (2017 ). Tamarixetin 3-O-beta-d-Glucopyranoside from Azadirachta indica Leaves: Gastroprotective Role through Inhibition of Matrix Metalloproteinase-9 Activity in Mice. J. Natural Prod. 80, 1347–1353.
Not in our library10.1021/acs.jnatprod.6b00957
452.
Yan C. Zhang W.-Q. Sun M. Liang W. Wang T.-Y. Zhang Y.-D. (2018 ). Carpescernolides A and B, rare oxygen bridge-containing sesquiterpene lactones from Carpesium cernuum. Tetrahedron Lett. 59, 4063–4066.
Not in our library10.1016/j.tetlet.2018.09.067
453.
Yang P.-F. Feng Z.-M. Yang Y.-N. Jiang J.-S. Zhang P.-C. (2017 ). Neuroprotective Caffeoylquinic Acid Derivatives from the Flowers of Chrysanthemum morifolium. J. Natural Prod. 80, 1028–1033.
Not in our library10.1021/acs.jnatprod.6b01026
454.
Yang G.-C. Hu J.-H. Li B.-L. Liu H. Wang J.-Y. Sun L.-X. (2018 ). Six New neo-Clerodane Diterpenoids from Aerial Parts of Scutellaria barbata and Their Cytotoxic Activities. Planta Med. 84, 1292–1299.
Not in our library10.1055/a-0638-8255
455.
Yang H. H. Oh K.-E. Jo Y. H. Ahn J. H. Liu Q. Turk A. (2018 ). Characterization of tyrosinase inhibitory constituents from the aerial parts of Humulus japonicus using LC-MS/MS coupled online assay. Bioorg. Med. Chem. 26, 509–515.
Not in our library10.1016/j.bmc.2017.12.011
456.
Yang X. Gao X. Cao Y. Guo Q. Li S. Zhu Z. (2018 ). Anti-Inflammatory Effects of Boldine and Reticuline Isolated from Litsea cubeba through JAK2/STAT3 and NF-κB Signaling Pathways. Planta Med. 84, 20–25.
Not in our library10.1055/s-0043-113447
457.
Yao X. Shan X. Zu L. (2018 ). Divergent Coupling of 2-Carbonyl-anilines and Diazo-cyclopentanones: Asymmetric Total Synthesis of (+)-Leucomidine A. Org. Lett. 20, 6498–6501.
Not in our library10.1021/acs.orglett.8b02823
458.
Ye X.-S. He J. Cheng Y.-C. Zhang L. Qiao H.-Y. Pan X.-G. (2017 ). Cornusides A-O, Bioactive Iridoid Glucoside Dimers from the Fruit of Cornus officinalis. J. Natural Prod. 80, 3103–3111.
Not in our library10.1021/acs.jnatprod.6b01127
459.
Yi L. Li Z. Yuan K. Qu X. Chen J. Wang G. (2004 ). Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells. J. Virol. 78, 11334–11339.
Not in our library10.1128/jvi.78.20.11334-11339.2004
460.
Yilmaz A. Crowley R. S. Sherwood A. M. Prisinzano T. E. (2017 ). Semisynthesis and Kappa-Opioid Receptor Activity of Derivatives of Columbin, a Furanolactone Diterpene. J. Natural Prod. 80, 2094–2100.
Not in our library10.1021/acs.jnatprod.7b00327
461.
Yoneyama T. Arai M. A. Akamine R. Koryudzu K. Tsuchiya A. Sadhu S. K. (2017 ). Notch Inhibitors from Calotropis gigantea That Induce Neuronal Differentiation of Neural Stem Cells. J. Natural Prod. 80, 2453–2461.
Not in our library10.1021/acs.jnatprod.7b00282
462.
Yongye A. B. Waddell J. Medina-Franco J. L. (2012 ). Molecular scaffold analysis of natural products databases in the public domain. Chem. Biol. Drug Des. 80, 717–724.
Not in our library10.1111/cbdd.12011
463.
Yu Y. Chang P. Yu H. Ren H. Hong D. Li Z. (2018 ). Productive Amyrin Synthases for Efficient α-Amyrin Synthesis in Engineered Saccharomyces cerevisiae. ACS Synth. Biol. 7, 2391–2402.
Not in our library10.1021/acssynbio.8b00176
464.
Yuan Z. Hu X. Zhang H. Liu L. Chen P. He M. (2018 ). Total synthesis of conosilane A via a site-selective C-H functionalization strategy. Chem. Commun. (Cambridge England) 54, 912–915.
Not in our library10.1039/c7cc09367e
465.
Zampieri M. Sekar K. Zamboni N. Sauer U. (2017 ). Frontiers of high-throughput metabolomics. Curr. Opin. Chem. Biol. 36, 15–23.
Not in our library10.1016/j.cbpa.2016.12.006
466.
Zani C. L. Carroll A. R. (2017 ). Database for Rapid Dereplication of Known Natural Products Using Data from MS and Fast NMR Experiments. J. Natural Prod. 80, 1758–1766.
Not in our library10.1021/acs.jnatprod.6b01093
467.
Zarev Y. Foubert K. Ionkova I. Apers S. Pieters L. (2017 ). Isolation and Structure Elucidation of Glucosylated Colchicinoids from the Seeds of Gloriosa superba by LC-DAD-SPE-NMR. J. Natural Prod. 80, 1187–1191.
Not in our library10.1021/acs.jnatprod.6b01024
468.
Zeng T. Wu X.-Y. Yang S.-X. Lai W.-C. Shi S.-D. Zou Q. (2017 ). Monoterpenoid Indole Alkaloids from Kopsia officinalis and the Immunosuppressive Activity of Rhazinilam. J. Natural Prod. 80, 864–871.
Not in our library10.1021/acs.jnatprod.6b00697
469.
Zhan G. Zhou J. Liu J. Huang J. Zhang H. Liu R. (2017 ). Acetylcholinesterase Inhibitory Alkaloids from the Whole Plants of Zephyranthes carinata. J. Natural Prod. 80, 2462–2471.
Not in our library10.1021/acs.jnatprod.7b00301
470.
Zhang M. Y. Barrow R. A. (2018 ). Total Synthesis of Boletopsin 11 Enabled by Directed ortho-C(sp(2))-H Arylation. J. Org. Chem. 83, 6776–6782.
Not in our library10.1021/acs.joc.8b00792
471.
Zhang C.-G. Chou G.-X. Mao X.-D. Yang Q.-S. Zhou J.-L. (2017 ). Nepetaefolins A-J, Cytotoxic Chinane and Abietane Diterpenoids from Caryopteris nepetaefolia. J. Natural Prod. 80, 1742–1749.
Not in our library10.1021/acs.jnatprod.6b00972
472.
Zhang C.-L. Hao Z.-Y. Liu Y.-F. Wang Y. Shi G.-R. Jiang Z.-B. (2017 ). Polycycloiridals with a Cyclopentane Ring from Iris tectorum. J. Natural Prod. 80, 156–161.
Not in our library10.1021/acs.jnatprod.6b00796
473.
Zhang D. Guo J. Zhang M. Liu X. Ba M. Tao X. (2017 ). Oxazole-Containing Diterpenoids from Cell Cultures of Salvia miltiorrhiza and Their Anti-HIV-1 Activities. J. Natural Prod. 80, 3241–3246.
Not in our library10.1021/acs.jnatprod.7b00659
474.
Zhang F. Barns K. Hoffmann F. M. Braun D. R. Andes D. R. Bugni T. S. (2017 ). Thalassosamide, a Siderophore Discovered from the Marine-Derived Bacterium Thalassospira profundimaris. J. Natural Prod. 80, 2551–2555.
Not in our library10.1021/acs.jnatprod.7b00328
475.
Zhang J.-F. Chen L. Huang S. Shan L.-H. Gao F. Zhou X.-L. (2017 ). Diterpenoid Alkaloids from Two Aconitum Species with Antifeedant Activity against Spodoptera exigua. J. Natural Prod. 80, 3136–3142.
Not in our library10.1021/acs.jnatprod.7b00380
476.
Zhang P.-L. Han Y. Zhang L.-T. Wang X.-L. Shen T. Ren D. (2017 ). Botrysphones A-C and Botrysphins A-F, Triketides and Diterpenoids from the Fungus Botrysphaeria laricina. J. Natural Prod. 80, 1791–1797.
Not in our library10.1021/acs.jnatprod.6b01196
477.
Zhang Y.-L. Zhou X.-W. Wu L. Wang X.-B. Yang M.-H. Luo J. (2017 ). Isolation, Structure Elucidation, and Absolute Configuration of Syncarpic Acid-Conjugated Terpenoids from Rhodomyrtus tomentosa. J. Natural Prod. 80, 989–998.
Not in our library10.1021/acs.jnatprod.6b01005
478.
Zhang H.-J. Rumschlag-Booms E. Guan Y.-F. Wang D.-Y. Liu K.-L. Li W.-F. (2017 a). Correction to Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant Justicia gendarussa. J. Natural Prod. 80, 2390.
Not in our library10.1021/acs.jnatprod.7b00562
479.
Zhang H.-J. Rumschlag-Booms E. Guan Y.-F. Wang D.-Y. Liu K.-L. Li W.-F. (2017 b). Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant Justicia gendarussa. J. Natural Prod. 80, 1798–1807.
Not in our library10.1021/acs.jnatprod.7b00004
480.
Zhang F.-M. Zhang S.-Y. Tu Y.-Q. (2018 ). Recent progress in the isolation, bioactivity, biosynthesis, and total synthesis of natural spiroketals. Nat. Prod. Rep. 35, 75–104.
Not in our library10.1039/c7np00043j
481.
Zhang J.-S. Weng H.-Z. Huang J.-L. Tang G.-H. Yin S. (2018 ). Anti-inflammatory Ingenane Diterpenoids from the Roots of Euphorbia kansui. Planta Med. 84, 1334–1339.
Not in our library10.1055/a-0646-4306
482.
Zhang M. Y. Malins L. R. Ward J. S. Barrow R. A. (2018 ). Total Synthesis of Suillusin. Org. Lett. 20, 7304–7307.
Not in our library10.1021/acs.orglett.8b03234
483.
Zhang W. Xiao D. Wang B. (2018 ). A concise total synthesis of cochlearoid B. Org. Biomolec. Chem. 16, 3358–3361.
Not in our library10.1039/c8ob00615f
484.
Zhang Y.-F. Zhu Z.-X. Sun H. Yao H.-N. Chen X.-N. Liu L. (2018 ). Stachyodin A, a pterocarpan derivative with unusual spirotetrahydrofuran ring from the roots of Indigofera stachyodes. Tetrahedron Lett. 59, 4514–4516.
Not in our library10.1016/j.tetlet.2018.11.024
485.
Zhao J. Feng J. Tan Z. Liu J. Zhao J. Chen R. (2017 ). Stachybotrysins A-G, Phenylspirodrimane Derivatives from the Fungus Stachybotrys chartarum. J. Natural Prod. 80, 1819–1826.
Not in our library10.1021/acs.jnatprod.7b00014
486.
Zhao J.-X. Fan Y.-Y. Xu J.-B. Gan L.-S. Xu C.-H. Ding J. (2017 ). Diterpenoids and Lignans from Cephalotaxus fortunei. J. Natural Prod. 80, 356–362.
Not in our library10.1021/acs.jnatprod.6b00802
487.
Zhao X. Park S. Y. Yang D. Lee S. Y. (2019 ). Synthetic Biology for Natural Compounds. Biochemistry 58, 1454–1456.
Not in our library10.1021/acs.biochem.8b00569
488.
Zheng D. Han L. Qu X. Chen X. Zhong J. Bi X. (2017 ). Cytotoxic Fusicoccane-Type Diterpenoids from Streptomyces violascens Isolated from Ailuropoda melanoleuca Feces. J. Natural Prod. 80, 837–844.
Not in our library10.1021/acs.jnatprod.6b00676
489.
Zheng Y. Zhang J. Wei L. Shi M. Wang J. Huang J. (2017 ). Gunnilactams A-C, Macrocyclic Tetralactams from the Mycelial Culture of the Entomogenous Fungus Paecilomyces gunnii. J. Natural Prod. 80, 1935–1938.
Not in our library10.1021/acs.jnatprod.7b00060
490.
Zheng T. Cheng L.-Z. Yan Y.-M. Xu F.-R. Tang X.-L. Li X.-Z. (2018 ). Compounds from the Roots of Codonopsis pilosula and Their SIRT1 Regulatory Activity. Natural Prod. Commun. 13, 37–40.
Not in our library10.1177/1934578x1801300112
491.
Zhou X.-J. Rahmani R. (1992 ). Preclinical and Clinical Pharmacology of Vinca Alkaloids. Drugs 44, 1–16.
Not in our library10.2165/00003495-199200444-00002
492.
Zhou S.-Y. Zhou T.-L. Qiu G. Huan X. Miao Z.-H. Yang S.-P. (2018 ). Three New Cytotoxic Monoterpenoid Bisindole Alkaloids from Tabernaemontana bufalina. Planta Med. 84, 1127–1133.
Not in our library10.1055/a-0608-4988
493.
Zhu M. Zhang X. Feng H. Dai J. Li J. Che Q. (2017 ). Penicisulfuranols A-F, Alkaloids from the Mangrove Endophytic Fungus Penicillium janthinellum HDN13-309. J. Natural Prod. 80, 71–75.
Not in our library10.1021/acs.jnatprod.6b00483
494.
Zhu G. Wang H. Gan K. Gao H. Li W. (2018 ). A New Purine Derivative from the Roots of Phyllanthus flexuosus. Natural Prod. Commun. 13, 41–44.
Not in our library10.1177/1934578x1801300113
495.
Zong Y. Wang W. Xu T. (2018 ). Total Synthesis of Bioactive Marine Meroterpenoids: The Cases of Liphagal and Frondosin B. Mar. Drugs 16, 155.
Not in our library10.3390/md16040115

Cited by papers we hold 2

Genome mining as a biotechnological tool for the discovery of novel biosynthetic genes in lichens · 2022
Not checked
Tick Salivary Compounds for Targeted Immunomodulatory Therapy · 2020
Not checked

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.